### Clinical Trials

NCCN believes that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, click here: [nccn.org/clinical_trials/physician.html](http://nccn.org/clinical_trials/physician.html).

### NCCN Categories of Evidence and Consensus

All recommendations are category 2A unless otherwise indicated.

See [NCCN Categories of Evidence and Consensus](http://nccn.org/clinical_trials/physician.html).

### NCCN Myelodysplastic Syndromes Panel Members

**Summary of Guidelines Updates**

- *Initial Evaluation (MDS-1)*
- *Additional Testing and Classification (MDS-2)*
- *Prognostic Category Low, Intermediate-1 Treatment (MDS-3)*
- *Evaluation of Related Anemia/Treatment of Symptomatic Anemia/Follow-up (MDS-5)*
- *Prognostic Category Intermediate-2, High Treatment (MDS-6)*
- *Supportive Care (MDS-7)*
- *2016 WHO Classification of MDS and Myelodysplastic/Myeloproliferative Neoplasms (MDS-A)*
- *Prognostic Scoring Systems (MDS-B)*
- *Frequent Mutations in MDS-Associated Genes Likely to Indicate Clonal Hematopoiesis (MDS-C)*
- *Germline Mutations with Predisposition for MDS/AML/MPN: Established & Emerging Familial Syndromes (MDS-C)*
- *Spectrum of Indolent Myeloid Hematopoietic Disorders (MDS-D)*
- *Recommendations for Flow Cytometry (MDS-E)*

---

**The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2018.**
Updates in Version 2.2018 of the NCCN Guidelines for Myelodysplastic Syndromes from Version 1.2018 include:

MS-1
• The discussion section was updated to reflect the changes in the algorithm.

Updates in Version 1.2018 of the NCCN Guidelines for Myelodysplastic Syndromes from Version 1.2017 include:

MDS-1
• Initial evaluation, added the following bullets that were previously on MDS-2:
  † "HIV testing if clinically indicated"
  † "Consider evaluation of copper deficiency in patients with GI malabsorption, severe malnutrition, gastric bypass surgery, or patients on zinc supplementation"
    ◊ "Severe malnutrition" was added to the above bullet.
  † "Consider distinction from congenital sideroblastic anemia (CSA)"
• Modified: "Diagnosis of MDS established based on morphologic, cytogenetic, and clinical criteria."
• Added a new pathway for "Diagnostic criteria for MDS not met but cytopenias present."
• Modified footnote "a": "MDS is also suspected in the presence of peripheral blood dysplasia, blasts, or MDS-associated cytogenetic abnormalities. Cytopenias are defined as values lower than standard lab hematologic levels, being cognizant of age, sex, ethnic, and altitude values. Greenberg PL, Tuechler H, Schanz J, et al. Blood 2016. 128 (16): 2096-2097."
• Modified footnote "b": "If standard cytogenetics (with ≥20 metaphases) not obtained, then MDS-related fluorescence in situ hybridization (FISH) panel eeuhd should be performed."
• Modified footnote "d": "Patients with karyotypes t(8;21), t(15;17), or inv(16) are considered to have AML even if the marrow blast count is less than 20%. (See NCCN Guidelines for AML)."
• Modified footnote "F": "Bone marrow or peripheral blood cells may be assayed for MDS-associated gene mutations. These can establish the presence of clonal hematopoiesis, which can help exclude benign causes of cytopenias in cases with non-diagnostic morphology, but do not establish a diagnosis of MDS in the absence of clinical diagnostic criteria. Certain gene mutations (negative prognostic factors: TP53, ASXL1, ETV6, RUNX1, and EZH2, positive prognostic factor: isolated SF3B1) can refine the prognosis of MDS in patients risk stratified by the IPSS or IPSS-R and may be helpful in patients predicted to have intermediate risk. Consider molecular testing for JAK2 mutation in MDS patients with thrombocytosis. (See Frequent Mutations in MDS-Associated Genes Likely to Indicate Clonal Hematopoiesis [MDS-C] and Discussion)."
• Modified footnote "g": "In younger patients, CSA is due to disordered mitochondrial heme synthesis, often with distinctive mutational and clinical features. Some of these patients will respond to pyridoxine or thiamine. CSA is not MDS. (Fleming MD, ASH Education Book vol.201(1), 525-531). Consider congenital bone marrow syndromes (eg, dyskeratosis congenita, Shwachman-Diamond syndrome)."

MDS-2
• Additional testing
  † Removed "Consider HLA-DR15 typing."
  † Previously listed on MDS-1, added "Consider additional genetic screening for patients with familial cytopenias, particularly for younger patients."
• Classification, removed "Indolent disease" pathway.
• Modified footnote "I": "Marrow or peripheral blood cell FCM may be assayed, and T-cell gene rearrangement studies may be conducted
Updates in Version 1.2018 of the NCCN Guidelines for Myelodysplastic Syndromes from Version 1.2017 include:

**MDS-3**

- **Treatment**
  - Modified "del(5q) ± one other cytogenetic abnormality (except those involving chromosome 7) IPSS Low/Intermediate 1."
  - Added: "Consider hypomethylating agents (if not already receiving)."

**MDS-4**

- Modified footnote "v": "Except for patients with low neutrophil counts or low platelet counts. Recommended initial dose is: 10 mg/d for 21 out of 28 days or 28 days monthly for 2 to 4 months to assess response (See Discussion). Alternative option to lenalidomide may include an initial trial of ESAs in patients with serum EPO ≤500 mU/mL. Use caution for patients with low platelet count; consider modifying lenalidomide dose. Sekeres MA, Maciejewski JP, Giagoundis AAN, et al. J Clin Oncol 2016; 26(36):5943-5949. Patients with monosomy 7 are an exception and should be treated in the higher prognostic risk category (see MDS-6).

**MDS-5 (formerly MDS-6)**

- Removed "Consider HLA-DR15 typing."
- Added footnote "aa": "Refers predominantly to low-risk IPSS-R and IPSS patients."

**MDS-6**

- Removed "MDS with excess blasts in transformation (MDS-EB-T)" from the table.
- Reworked footnote "2": "The 2016 WHO classification for AML includes entity 'AML with myelodysplasia-related changes' that encompasses patients who were previously categorized in the FAB classification of MDS as RAEB-T. AML evolving from MDS (AML-MDS) is often more resistant to cytotoxic chemotherapy than AML that arises without antecedent hematologic disorder and may have a more indolent course. Some clinical trials designed for high-grade MDS may allow enrollment of patients with AML-MDS. Patients with 20% to 29% marrow blasts AND a stable clinical course for at least 2 months may be considered as either MDS or AML and may be more akin to MDS (prior FAB RAEB-T) than to AML. Such patients may be considered for treatment as either MDS or AML. Individuals with FLT3 and NPM1 mutations are more likely to be AML than MDS. See Discussion.

**MDS-C (1 of 4)**

- Added "STAT3" and "PPM1D" to the table.

**MDS-C (2 of 4)**

- Added two new references to the list:
Updates in Version 1.2018 of the NCCN Guidelines for Myelodysplastic Syndromes from Version 1.2017 include:

**MDS-C (3 of 4)**
- Added "SBDS" to the table.
- Added two new references to the list:

**MDS-D**

**MDS-E**
- Added two new bullets:
  - "Flow cytometric abnormalities are often seen in MDS, and in some cases may correlate with observed morphologic abnormalities. They may also help diagnostically in patients with clinical suspicion of MDS who have no significant morphologic dysplasia and whose chromosome/FISH studies are either negative or normal."
  - "FCM is most useful in detecting aberrant immature myeloid lineages often observed in myelodysplastic syndromes. Flow analysis will detect aberrant expression of B or T cell antigens on myeloid precursors, and selective loss or gain of additional markers (eg, loss or dim expression of CD 33, CD34, CD56, CD38, or CD117) on myeloid precursors. Flow will help in cytopenia associated with LGL expansion by detecting increase of CD56/CD57+ cells. CMMML-associated monocytic aberrancies can be easily detected by combination of CD64/CD14, and CD16 loss or dim expression. In addition, qualitative abnormalities in mature myeloid lineages, eg, hypogranular late myelocytes, bands/Pelger-Huet cells and neutrophils will have abnormal flow patterns (low or negative for CD16 or CD10). However, the erythroid lineage dysplasia (dyserythropoiesis) detection by FCM is limited due to variable RBC lysing methods used in preparing flow mononuclear cell suspension. Megakaryocytic dysplasia cannot be assessed in FCM."
- Added references:
INITIAL EVALUATION

Cytopenia(s), suspect myelodysplasia\(^a\)

- H&P
- Complete blood count (CBC), platelets, differential, reticulocyte count
- Examination of peripheral smear
- Bone marrow aspiration with iron stain + biopsy + cytogenetics by standard karyotyping\(^b\)
- Serum erythropoietin (prior to RBC transfusion)
- Red blood cell (RBC) folate, serum B\(_12\)\(^e\)
- Serum ferritin, iron, total iron-binding capacity (TIBC)
- Documentation of transfusion history
- Thyroid-stimulating hormone (TSH)
- Lactate dehydrogenase (LDH)
- Consider molecular testing for recurrently mutated MDS genes in appropriate clinical contexts\(^f\)
- HIV testing if clinically indicated
- Consider evaluation of copper deficiency in patients with GI malabsorption, severe malnutrition, gastric bypass surgery, or patients on zinc supplementation
- Consider distinction from congenital sideroblastic anemia (CSA)\(^g\)

Diagnosis of MDS established based on morphologic, cytogenetic, and clinical criteria\(^c,d\)

Diagnostic criteria for MDS not met but cytopenias present

\(^a\)MDS is also suspected in the presence of peripheral blood dysplasia, blasts, or MDS-associated cytogenetic abnormalities. Cytopenias are defined as values lower than standard lab hematologic levels, being cognizant of age, sex, ethnic, and altitude norms . Greenberg PL, Tuechler H, Schanz J, et al. Blood 2016;128(16):2096-2097.

\(^b\)If standard cytogenetics (with ≥20 metaphases) not obtained, then MDS-related fluorescence in situ hybridization (FISH) panel should be performed.

\(^c\)Confirm diagnosis of MDS according to WHO/NCCN criteria for classification (See MDS-A) with application of IPSS or IPSS-R. (See MDS-B). The percentage of marrow myeloblasts based on morphologic assessment (aspirate smears preferred) should be reported. Flow cytometric estimation of blast percentage should not be used as a substitute for morphology in this context. In expert hands, expanded flow cytometry may be a useful adjunct for diagnosis in difficult cases. (See Initial Evaluation in the Discussion).

\(^d\)Patients with karyotypes t(8;21), t(15;17), or inv(16) are considered to have AML even if the marrow blast count is less than 20%. (See NCCN Guidelines for AML).

\(^e\)RBC folate is a more representative measure of folate stores and is the preferred test to serum folate. Serum methylmalonic acid testing is an accurate way to assess B\(_12\) status.

\(^f\)Bone marrow or peripheral blood cells may be assayed for MDS-associated gene mutations. These can establish the presence of clonal hematopoiesis, which can help exclude benign causes of cytopenias in cases with non-diagnostic morphology, but do not establish a diagnosis of MDS in the absence of clinical diagnostic criteria. Certain gene mutations (negative prognostic factors: TP53, ASXL1, ETV6, RUNX1, and EZH2; positive prognostic factor: isolated SF3B1) can refine the prognosis of MDS in patients risk stratified by the IPSS or IPSS-R and may be helpful in patients predicted to have intermediate risk. Consider molecular testing for JAK2 mutation in MDS patients with thrombocytosis. (See Frequent Mutations in MDS-Associated Genes Likely to Indicate Clonal Hematopoiesis [MDS-C] and Discussion).

\(^g\)In younger patients, CSA is due to disordered mitochondrial heme synthesis, often with distinctive mutational and clinical features. Some of these patients will respond to pyridoxine or thiamine. CSA is not MDS. (Fleming MD, ASH Education Book vol.2011(1),525-531). Consider congenital bone marrow syndromes (eg, dyskeratosis congenita, Shwachman-Diamond syndrome) See MDS-C.
• Consider flow cytometry (FCM) for MDS as a diagnostic aid to assess for possible large granular lymphocyte (LGL) disease and to evaluate for a paroxysmal nocturnal hemoglobinuria (PNH) clone.
• Human leukocyte antigen (HLA) typing if hematopoietic cell transplant (HCT) candidate.
• HLA typing if platelet support is indicated.
• Evaluate patients with chronic myelomonocytic leukemia (CMML) for 5q31-33 translocations and/or PDGFRβ gene rearrangements.
• Consider additional genetic screening for patients with familial cytopenias, particularly for younger patients.

**ADDITIONAL TESTING**

**CLASSIFICATION**

- MDS
  - See Classification Systems (MDS-A and MDS-B)
- Acute myeloid leukemia (AML)
  - See NCCN Guidelines for AML

---

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
**PROGNOSTIC CATEGORY**

- **IPSS-R**: Very Low, Low, Intermediate<sup>o,p</sup>
- **IPSS**: Low/Intermediate-1
- **WPSS**: Very Low, Low, Intermediate

**TREATMENT**

- **Symptomatic anemia**
  - **Clinically significant cytopenia(s) or increased marrow blasts**
    - Supportive care<sup>q</sup> as an adjunct to treatment

- **No del(5q) ± other cytogenetic abnormalities**
  - **Serum EPO ≤500 mU/mL** → See MDS-4
  - **Serum EPO >500 mU/mL** → See MDS-4

- **Clinically relevant thrombocytopenia or neutropenia or increased marrow blasts**
  - Azacitidine or Decitabine or Immunosuppressive therapy (IST) for select patients<sup>r</sup>
  - Disease progression/No response<sup>s</sup>
  - Consider hypomethylating agents (if not already receiving)<sup>t</sup>
  - Clinical trial or Consider allo-HCT for select patients<sup>u</sup>

<sup>n</sup>Presence of comorbidities should also be considered for evaluation of prognosis. *(See Comorbidity Indices in the Discussion.)*

<sup>o</sup>Given its more accurate risk stratification, the IPSS-R categorization is preferred although the other systems also have good value. IPSS-R Intermediate patients may be managed as lower risk if their score ≤3.5 vs. higher risk if score >3.5. Pfeilstöcker M, Tuechler H, Sanz G, et al. Blood 2016;128(7):902-910.

<sup>p</sup>If the disease is initially managed as lower risk but fails to respond, move to higher risk management strategies.

<sup>q</sup>See Supportive Care (MDS-7).

<sup>o</sup>Patients generally ≤60 y and with ≤5% marrow blasts, or those with hypocellular marrows, PNH clone positivity, or STAT-3 mutant cytotoxic T-cell clones. IST includes equine ATG ± cyclosporin A.

<sup>s</sup>Response should be evaluated based on IWG criteria: Cheson BD, Greenberg PL, Bennett JM, et al. Blood 2006;108:419-425. Failure would be considered if no response within 3–6 mo.


<sup>r</sup>IPSS Intermediate-1, IPSS-R Intermediate, and WPSS Intermediate patients with severe cytopenias would also be considered candidates for HCT. Both allogeneic-matched sibling and matched unrelated donor (MUD) transplants, including standard and reduced-intensity preparative approaches, may be considered.

---

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
**PROGNOSTIC CATEGORY**

- IPSS-R: Very Low, Low, Intermediate
- IPSS: Low/Intermediate-1
- WPSS: Very Low, Low, Intermediate

**TREATMENT**

<table>
<thead>
<tr>
<th>Symptomatic anemia with del(5q) ± one other cytogenetic abnormality (except those involving chromosome 7)</th>
<th>Lenalidomide&lt;sup&gt;v&lt;/sup&gt;</th>
<th>No response&lt;sup&gt;s&lt;/sup&gt; or intolerance</th>
<th>Follow appropriate pathway below</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum EPO ≤500 mU/mL</td>
<td>Epoetin alfa (rHu EPO) ± G-CSF&lt;sup&gt;W&lt;/sup&gt; or Darbepoetin alfa ± G-CSF&lt;sup&gt;W&lt;/sup&gt;</td>
<td>No response after 3 mo or erythroid response followed by loss of response&lt;sup&gt;s&lt;/sup&gt;</td>
<td>Lenalidomide&lt;sup&gt;x&lt;/sup&gt; or rHu EPO ± G-CSF&lt;sup&gt;W&lt;/sup&gt; or Lenalidomide&lt;sup&gt;x&lt;/sup&gt; + Darbepoetin alfa ± G-CSF&lt;sup&gt;W&lt;/sup&gt;</td>
</tr>
<tr>
<td>Symptomatic anemia with no del(5q)</td>
<td>Good probability to respond to IST&lt;sup&gt;r&lt;/sup&gt;</td>
<td>ATG&lt;sup&gt;z&lt;/sup&gt; ± Cyclosporin A</td>
<td>No response&lt;sup&gt;s&lt;/sup&gt; or intolerance</td>
</tr>
<tr>
<td>Serum EPO &gt;500 mU/mL</td>
<td>Poor probability to respond to IST&lt;sup&gt;y&lt;/sup&gt;</td>
<td>Lenalidomide&lt;sup&gt;x&lt;/sup&gt; + rHu EPO ± G-CSF&lt;sup&gt;W&lt;/sup&gt; or Lenalidomide&lt;sup&gt;x&lt;/sup&gt; + Darbepoetin alfa ± G-CSF&lt;sup&gt;W&lt;/sup&gt;</td>
<td>No response&lt;sup&gt;s&lt;/sup&gt; or intolerance</td>
</tr>
</tbody>
</table>

<sup>n</sup>Presence of comorbidities should also be considered for evaluation of prognosis. (See Comorbidity Indices in the Discussion.)

<sup>o</sup>Given its more accurate risk stratification, the IPSS-R categorization is preferred although the other systems also have good value. IPSS-R Intermediate patients may be managed as lower risk if their score is ≤3.5 vs. higher risk if score is >3.5. Pfeilstöcker M, Tuechler H, Sanz G, et al. Blood 2016;128(7):902-910.

<sup>p</sup>Given disease is initially managed as lower risk but fails to respond, move to higher risk management strategies.

<sup>q</sup>Patients generally ≤60 y and with ≤5% marrow blasts, or those with hypocellular marrows, PNH clone positivity, or STAT-3 mutant cytotoxic T-cell clones. IST includes equine ATG ± cyclosporin A.

<sup>r</sup>Response should be evaluated based on IWG criteria: Cheson BD, Greenberg PL, Bennett JM, et al. Blood 2006;108:419-425. Failure would be considered if no response within 3–6 mo.

<sup>s</sup>IPSS Intermediate-1, IPSS-R Intermediate, and WPSS Intermediate patients with severe cytopenias would also be considered candidates for HCT. Both allogeneic-matched sibling and matched unrelated donor (MUD) transplants, including standard and reduced-intensity preparative approaches, may be considered.

<sup>t</sup>Except for patients with low neutrophil counts or low platelet counts. Recommended initial dose is: 10 mg/d for 21 out of 28 days or 28 days monthly for 2–4 months to assess response (See Discussion). Alternative option to lenalidomide may include an initial trial of ESAs in patients with serum EPO ≤500 mU/mL. Use caution for patients with low platelet count; consider modifying lenalidomide dose. Sekeres MA, Maciejewski JP, Giagounidis AAN, et al. J Clin Oncol 2016;26(36):5943-5949. Patients with monosomy 7 are an exception and should be treated in the higher prognostic risk category (see MDS-6).

<sup>W</sup>See dosing of hematopoietic cytokines (MDS-5).

<sup>x</sup>Lenalidomide 10 mg daily if ANC > 0.5, platelets > 50,000; Toma A, Kosmider O, Chevret S, et al. Leukemia. 2016;30(4):897-905.

<sup>y</sup>Patients lack features listed in footnote s.

<sup>z</sup>Equine ATG ± cyclosporin A has been used in patients with MDS (See Discussion).
EVALUATION OF RELATED ANEMIA

- H&P
- CBC, platelets, differential, reticulocyte count
- Examination of peripheral smear
- Bone marrow aspiration with iron stain + biopsy + cytogenetics
- Serum EPO level
- Rule out coexisting causes

TREATMENT OF SYMPTOMATIC ANEMIA

- Treat coexisting causes
- Replace iron, folate, B₁₂ if needed
- RBC transfusions (leuko-reduced)
- Supportive care

FOLLOW-UP

- Continue lenalidomide, decrease dose to tolerance
- Continue EPO, decrease dose to tolerance
- Consider adding G-CSF 1–2 mcg/kg 1–2 x/wk subcutaneous

DEL(5q) ± one other cytogenetic abnormality (except those involving chromosome 7)

Lenalidomide

Response

No response

See (MDS-4)

Serum EPO ≤500 mU/mL

Ring sideroblasts <15%

rHu EPO 40,000–60,000 U 1–2 x/wk subcutaneous or Darbepoetin alfa 150–300 mcg every other wk subcutaneous

Response

No response

See (MDS-4)

Serum EPO ≤500 mU/mL

Ring sideroblasts ≥15%

rHu EPO 40,000–60,000 U 1–2 x/wk subcutaneous + G-CSF 1–2 mcg/kg 1–2 x/wk subcutaneous or Darbepoetin alfa 150–300 mcg every other wk subcutaneous + G-CSF 1–2 mcg/kg 1–2 x/wk subcutaneous

Response

No response

See (MDS-4)

Serum EPO >500 mU/mL

See (MDS-4)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

See Supportive Care (MDS-7).


aaRefers predominantly to lower risk IPSS-R and IPSS patients.

bbIn some institutions, darbepoetin alfa has been administered using doses up to 500 mcg every other week.

CcLack of 1.5 gm/dL rise in hemoglobin or lack of a decrease in RBC transfusion requirement by 3 to 4 months of treatment.

ddTarget Hb range 10 to 12 g/dL; not to exceed 12 g/dL.

eeLack of 1.5 gm/dL rise in hemoglobin or lack of a decrease in RBC transfusion requirement by 6 to 8 weeks of treatment.
IPSS-R: Intermediate, High, Very High
IPSS: Intermediate-2, High
WPSS: High, Very High

Transplant candidate?

Donor stem cell source available:

Yes

No

TREATMENT

Allo-HCT or Azacitidine followed by HCT or Decitabine followed by HCT

Relapse after HCT or No response

Consider HCT or donor lymphocyte infusion or Azacitidine or Decitabine or Clinical trial

Response — Continue

No response or relapse

Response — Clinical trial or Supportive care

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
SUPPORTIVE CARE

- Clinical monitoring
- Psychosocial support (See NCCN Guidelines for Survivorship)
- Quality-of-life assessment
- Transfusions:
  - RBC transfusions (leuko-reduced) are recommended for symptomatic anemia, and platelet transfusions are recommended for thrombocytopenic bleeding. However, they should not be used routinely in patients with thrombocytopenia in the absence of bleeding unless platelet count <10,000/mcL. Irradiated products are suggested for transplant candidates.
  - Cytomegalovirus (CMV)-negative or leuko-reduced blood products are recommended whenever possible for CMV-negative transplant candidates.
- Antibiotics are recommended for bacterial infections, but no routine prophylaxis is recommended except in patients with recurrent infections.
- Aminocaproic acid or other antifibrinolytic agents may be considered for bleeding refractory to platelet transfusions or profound thrombocytopenia.
- Iron chelation:
  - If >20 to 30 RBC transfusions have been received, consider daily chelation with deferoxamine subcutaneously or deferasirox orally to decrease iron overload, particularly for patients who have lower-risk MDS or who are potential transplant candidates LOW/INT-1. For patients with serum ferritin levels >2500 ng/mL, aim to decrease ferritin levels to <1000 ng/mL. (See Discussion)
  - Patients with low creatinine clearance (<40 mL/min) should not be treated with deferasirox or deferoxamine.
- Cytokines:
  - EPO: See Anemia Pathway (MDS-5)
  - G-CSF or GM-CSF:
    - Not recommended for routine infection prophylaxis.
    - Consider use in neutropenic patients with recurrent or resistant infections.
    - Combine with EPO for anemia when indicated. See Anemia Pathway (MDS-5).
    - Platelet count should be monitored.
- Clinically significant thrombocytopenia
  - In patients with lower-risk MDS who have severe or life-threatening thrombocytopenia, consider treatment with a thrombopoietin-receptor agonist.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
### 2016 WHO CLASSIFICATION OF MDS<sup>1,2</sup>

<table>
<thead>
<tr>
<th>Subtype</th>
<th>Blood</th>
<th>Bone marrow</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDS with single lineage dysplasia (MDS-SLD)&lt;sup&gt;3&lt;/sup&gt;</td>
<td>Single or bicytopenia</td>
<td>Dysplasia in ≥10% of one cell line, &lt;5% blasts</td>
</tr>
<tr>
<td>MDS with ring sideroblasts (MDS-RS)</td>
<td>Anemia, no blasts</td>
<td>≥15% of erythroid precursors w/ring sideroblasts, or ≥5% ring sideroblasts if SF3B1 mutation present</td>
</tr>
<tr>
<td>MDS with multilineage dysplasia (MDS-MLD)</td>
<td>Cytopenia(s), &lt;1 x 10&lt;sup&gt;9&lt;/sup&gt;/L monocytes</td>
<td>Dysplasia in ≥10% of cells in ≥2 hematopoietic lineages, ± 15% ring sideroblasts, &lt;5% blasts</td>
</tr>
<tr>
<td>MDS with excess blasts-1 (MDS-EB-1)</td>
<td>Cytopenia(s), ≤2%–4% blasts, &lt;1 x 10&lt;sup&gt;9&lt;/sup&gt;/L monocytes</td>
<td>Unilineage or multilineage dysplasia, 5%–9% blasts, no Auer rods</td>
</tr>
<tr>
<td>MDS with excess blasts-2 (MDS-EB-2)</td>
<td>Cytopenia(s), 5%–19% blasts, &lt;1 x 10&lt;sup&gt;9&lt;/sup&gt;/L monocytes</td>
<td>Unilineage or multilineage dysplasia, 10%–19% blasts, ± Auer rods</td>
</tr>
<tr>
<td>MDS, unclassifiable (MDS-U)</td>
<td>Cytopenias, ±1% blasts on at least 2 occasions</td>
<td>Unilineage dysplasia or no dysplasia but characteristic MDS cytogenetics, &lt;5% blasts</td>
</tr>
<tr>
<td>MDS with isolated del(5q)</td>
<td>Anemia, platelets normal or increased</td>
<td>Unilineage erythroid dysplasia, isolated del(5q), &lt;5% blasts</td>
</tr>
<tr>
<td>Refractory cytopenia of childhood</td>
<td>Cytopenias, &lt;2% blasts</td>
<td>Dysplasia in 1–3 lineages, &lt;5% blasts</td>
</tr>
</tbody>
</table>

---


<sup>2</sup>The 2016 WHO classification for AML includes entity “AML with myelodysplasia-related changes” that encompasses patients who were previously categorized in the FAB classification of MDS as RAEB-T. AML evolving from MDS (AML-MDS) is often more resistant to cytotoxic chemotherapy than AML that arises without antecedent hematologic disorder and may have a more indolent course. Some clinical trials designed for high-grade MDS may allow enrollment of patients with AML-MDS. Patients with 20% to 29% marrow blasts AND a stable clinical course for at least 2 months may be considered as either MDS or AML and may be more akin to MDS (prior FAB RAEB-T) than to AML. Such patients may be considered for treatment as either MDS or AML. Individuals with FLT3 and NPM1 mutations are more likely to be AML than MDS. See Discussion.

<sup>3</sup>This category encompasses refractory anemia (RA), refractory neutropenia (RN), and refractory thrombocytopenia (RT). Cases of RN and RT were previously classified as MDS, unclassified.

---

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
### MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS (MDS/MPN) WHO CLASSIFICATION

<table>
<thead>
<tr>
<th>Subtype</th>
<th>Blood</th>
<th>Marrow</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic myelomonocytic leukemia (CMML)-0</td>
<td>&gt;1x10⁹/L monocytes, &lt;2% blasts</td>
<td>Dysplasia in ≥1 hematopoietic line, &lt;5% blasts</td>
</tr>
<tr>
<td>Chronic myelomonocytic leukemia (CMML)-1</td>
<td>≥1x10⁹/L monocytes, 2%–4% blasts</td>
<td>Dysplasia in ≥1 hematopoietic line, 5%–9% blasts</td>
</tr>
<tr>
<td>CMML-2</td>
<td>≥1x10⁹/L monocytes, 5%–19% blasts or Auer rods</td>
<td>Dysplasia in ≥1 hematopoietic line, 10%–19% blasts or Auer rods</td>
</tr>
<tr>
<td>Atypical chronic myeloid leukemia (aCMLL), BCR-ABL1 negative</td>
<td>WBC ≥13x10⁹/L, neutrophil precursors &gt;10%, &lt;20% blasts, dysgranulopoiesis</td>
<td>Hypercellular, &lt;20% blasts</td>
</tr>
<tr>
<td>Chronic neutrophilic leukemia (CNL)</td>
<td>WBC ≥25,000 with PMN/bands ≥80%, no dysplasia</td>
<td>Mature myeloid hyperplasia, &lt;5% blasts, no dysplasia</td>
</tr>
<tr>
<td>Juvenile myelomonocytic leukemia (JMML)</td>
<td>≥1x10⁹/L monocytes, &lt;20% blasts</td>
<td>≥1x10⁹/L monocytes, &lt;20% blasts</td>
</tr>
<tr>
<td>MDS/MPN, unclassifiable (“Overlap syndrome”)</td>
<td>Dysplasia + myeloproliferative features, No prior MDS or MPN</td>
<td>Dysplasia + myeloproliferative features</td>
</tr>
<tr>
<td>MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)</td>
<td>Dysplasia + myeloproliferative features, Platelets ≥450x10⁹/L, ≥15% ring sideroblasts</td>
<td>Dysplasia + myeloproliferative features</td>
</tr>
</tbody>
</table>


2CMML patients with WBC <13,000 and <5% marrow blasts (CMML)-0 have a better prognosis. Schuler E, Schroeder M, Neukirchen J, et al. Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias, Leuk Res 2014;38:1413-9. The most frequently mutated genes in CMML are TET2 (40%–60%), SRSF2 (40%–50%), ASXL1 (40%–50%), RUNX1 (15%–20%), NRAS (10%–20%), and CBL (10%–20%) - although none are exclusive to this disease subtype and some patients with CMML will not have mutations in these genes. Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood Oct 11 2012;120(15):3080-3088.

5Often associated with SETBP1 and/or ETNK1 mutations.

6Often associated with CSF3 receptor (GCSFR) mutation, no evidence for CML or other MPN.

7The most frequently mutated genes in JMML are PTPN11 (40%–50%), NRAS (15%–20%), KRAS (10%–15%), CBL (15%–18%), and NFI (10%–15%) - although none are exclusive to this disease subtype. In some patients, these mutations may be present as germline variants where they are frequently associated with Noonan syndrome or other congenital syndromes. Sakaguchi H, Okuno Y, Muramatsu H, et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet Aug 2013;45(8):937-941.

8Ph negative plus ≥2 features: hemoglobin F, peripheral blood immature myeloid cells, WBC > 10x10⁹/L, clonal chromosomal abnormality, and GM-CSF hypersensitivity in vitro.

9Examples include thrombocytosis, leukocytosis, and splenomegaly.

10Frequently mutated genes in MDS/MPN-RS-T are SF3B1 and JAK2.
**INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS)¹,²**

<table>
<thead>
<tr>
<th>Prognostic variable</th>
<th>Score value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marrow blasts (%)³</td>
<td>&lt;5 5-10 11-20 21-30</td>
</tr>
<tr>
<td>Karyotype⁴</td>
<td>Good Intermediate Poor</td>
</tr>
<tr>
<td>Cytopenia⁵</td>
<td>0/1 2/3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IPSS Risk category (% IPSS pop.)</th>
<th>Overall score</th>
<th>Median survival (y) in the absence of therapy</th>
<th>25% AML progression (y) in the absence of therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOW (33)</td>
<td>0</td>
<td>5.7</td>
<td>9.4</td>
</tr>
<tr>
<td>INT-1 (38)</td>
<td>0.5-1.0</td>
<td>3.5</td>
<td>3.3</td>
</tr>
<tr>
<td>INT-2 (22)</td>
<td>1.5-2.0</td>
<td>1.1</td>
<td>1.1</td>
</tr>
<tr>
<td>HIGH (7)</td>
<td>≥2.5</td>
<td>0.4</td>
<td>0.2</td>
</tr>
</tbody>
</table>

For IPSS: Low/Intermediate-1 see MDS-3 and MDS-4
For IPSS: Intermediate-2/High see MDS-5

¹IPSS should be used for initial prognostic and planning purposes. WPSS permits dynamic estimation of prognosis at multiple time points during the course of MDS.
³Patients with 20%–29% blasts may be considered to have MDS (FAB) or AML (WHO).
⁴Cytogenetics: Good = normal, -Y alone, del(5q) alone, del(20q) alone; Poor = complex (≥3 abnormalities) or chromosome 7 anomalies; Intermediate = other abnormalities. [This excludes karyotypes t(8;21), inv16, and t(15;17), which are considered to be AML and not MDS.]
⁵Cytopenias: neutrophil count <1,800/mcL, platelets <100,000/mcL, Hb <10g/dL.

**REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS-R⁶)**

<table>
<thead>
<tr>
<th>Prognostic variable</th>
<th>Score value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytogenetic⁷</td>
<td>Very good   —</td>
</tr>
<tr>
<td>Marrow blasts (%)⁵</td>
<td>≤2 &gt;2-5&gt;5 5-10 &gt;10 —</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>≥10 8-10 &lt;8 — — — —</td>
</tr>
<tr>
<td>Platelets</td>
<td>≥100 50-100 &lt;100 — — — —</td>
</tr>
<tr>
<td>ANC</td>
<td>≥0.8 &lt;0.8 — — — —</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IPSS-R Risk category (% IPSS-R pop.)</th>
<th>Overall score</th>
<th>Median survival (y) in the absence of therapy</th>
<th>25% AML progression (y) in the absence of therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>VERY LOW (19)</td>
<td>≤1.5</td>
<td>8.8</td>
<td>Not reached</td>
</tr>
<tr>
<td>LOW (38)</td>
<td>&gt;1.5-3.0</td>
<td>5.3</td>
<td>10.8</td>
</tr>
<tr>
<td>INT⁸ (20)</td>
<td>&gt;3.0-4.5</td>
<td>3</td>
<td>3.2</td>
</tr>
<tr>
<td>HIGH (13)</td>
<td>&gt;4.5-6.0</td>
<td>1.6</td>
<td>1.4</td>
</tr>
<tr>
<td>VERY HIGH (10)</td>
<td>&gt;6.0</td>
<td>0.8</td>
<td>0.7</td>
</tr>
</tbody>
</table>

For IPSS-R: Very Low/Low/Intermediate, see MDS-3 and MDS-4
For IPSS-R: Intermediate/High/Very High, see MDS-5


⁷Cytogenetic risks: Very good = -Y, del(11q): Good = normal, del(5q), del(12p), del(20q), double including del(5q); Intermediate = del(7q), +8, +19, i(17q), any other single or double independent clones; Poor = -7, inv(3)/t(3q)/del(3q), double including -7/del(7q), complex: (3 abnormalities); Very poor = complex: >3 abnormalities.
WHO-BASED PROGNOSTIC SCORING SYSTEM (WPSS)\textsuperscript{8,9}

<table>
<thead>
<tr>
<th>Variable</th>
<th>Variable scores</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>WHO category</td>
<td>RCUD, RARS, MDS with isolated del(5q)</td>
</tr>
<tr>
<td>Karyotype\textsuperscript{4}</td>
<td>Good</td>
</tr>
<tr>
<td>Severe anemia (hemoglobin &lt;9 g/dL in males or &lt;8 g/dL in females)</td>
<td>Absent</td>
</tr>
</tbody>
</table>

\begin{tabular}{|l|c|c|c|c|}
\hline
\textbf{WPSS Risk} & \textbf{Sum of individual variable scores} & \textbf{Median survival (y) from diagnosis} & \textbf{Median time (y) to AML progression from diagnosis} \\
\hline
Very Low & 0 & 11.6 & NR \\
Low & 1 & 9.3 & 14.7 \\
Intermediate & 2 & 5.7 & 7.8 \\
High & 3–4 & 1.8 & 1.8 \\
Very High & 5–6 & 1.1 & 1.0 \\
\hline
\end{tabular}

For WPSS: Very Low/Low/Intermediate see MDS-3 and MDS-4
For WPSS: High/Very High see MDS-5

\textsuperscript{4}Cytogenetics: Good = normal, -Y alone, del(5q) alone, del(20q) alone; Poor = complex (≥3 abnormalities) or chromosome 7 anomalies; Intermediate = other abnormalities. [This excludes karyotypes t(8;21), inv16, and t(15;17), which are considered to be AML and not MDS.]


Frequent Mutations in MDS-Associated Genes Likely to Indicate Clonal Hematopoiesis

Table: This table lists gene mutations likely to be somatic (acquired, not congenital) and disease-related and therefore presumptive evidence of MDS. Other mutations in these genes can occur in MDS, as can mutations in other frequently mutated genes like TET2 and DNMT3A, but these may have less certain significance (ie, possible germline variants or less specific for MDS). All mutated genes are not unique to MDS and must be interpreted in the appropriate clinical context (eg, cytopenias, <20% bone marrow blasts, no other AML defining criteria). Not all MDS patients will have a mutation in one of these genes.

<table>
<thead>
<tr>
<th>Mutated Gene</th>
<th>Examples of Typical Somatic Mutation Types and Locations in Select MDS-Related Genes</th>
<th>Overall Incidence</th>
<th>Clinical Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>TET2</td>
<td>Nonsense or Frameshift or Splice Site Misssense: any in codons 1134–1444 or 1842–1921</td>
<td>20%–25%</td>
<td>Associated with normal karyotypes. More frequent in CMML (40%–60%).</td>
</tr>
<tr>
<td>DNMT3A</td>
<td>Nonsense or Frameshift or Splice Site Misssense: in codon R882</td>
<td>12%–18%</td>
<td>More frequent occurrence in AML.</td>
</tr>
<tr>
<td>ASXL1</td>
<td>Nonsense or Frameshift</td>
<td>15%–25%</td>
<td>Independently associated with a poor prognosis in MDS and CMML. More frequent in CMML (40%–90%).</td>
</tr>
<tr>
<td>EZH2</td>
<td>Nonsense or Frameshift</td>
<td>5%–10%</td>
<td>Independently associated with a poor prognosis in MDS and AML. More frequent in CMML (12%).</td>
</tr>
<tr>
<td>SF3B1</td>
<td>Misssense: E622, Y623, R625, N626, H662, T663, K666, K700E, I704, G740, GT42, D781</td>
<td>20%–30%</td>
<td>Strongly associated with ring sideroblasts and more frequent in MDS-RS (80%). Independently associated with a more favorable prognosis.</td>
</tr>
<tr>
<td>SRSF2</td>
<td>Misssense: P95</td>
<td>10%–15%</td>
<td>More frequent in CMML (40%) and associated with a poor prognosis.</td>
</tr>
<tr>
<td>U2AF1</td>
<td>Misssense: S34, Q157</td>
<td>8%–12%</td>
<td>Associated with a poor prognosis.</td>
</tr>
<tr>
<td>ZRSR2</td>
<td>Nonsense or Frameshift</td>
<td>5%–10%</td>
<td>Associated with a poor prognosis.</td>
</tr>
<tr>
<td>TP53</td>
<td>Nonsense or Frameshift or Splice Site Misssense: any in codons except P47S and P72R</td>
<td>8%–12%</td>
<td>Independently associated with a poor prognosis. More frequent with complex karyotypes (50%) and del(5q) (15%–20%). May predict resistance or relapse to lenalidomide.</td>
</tr>
<tr>
<td>STAG2</td>
<td>Nonsense or Frameshift or Splice Site</td>
<td>5%–10%</td>
<td>Associated with a poor prognosis.</td>
</tr>
<tr>
<td>NRAS</td>
<td>Misssense: G12, G13, Q61</td>
<td>5%–10%</td>
<td>Associated with a poor prognosis, particularly in patients predicted to have lower-risk MDS. More frequent in CMML and JMML (~15%).</td>
</tr>
<tr>
<td>CBL</td>
<td>Misssense: any in codons 366–420</td>
<td>&lt;5%</td>
<td>More frequent in CMML (10%–20%) and JMML (15%).</td>
</tr>
<tr>
<td>JAK2</td>
<td>Misssense: V617F</td>
<td>&lt;5%</td>
<td>More frequent in MDS/MPN-RS-T (50%); can occur in conjunction with SF3B1</td>
</tr>
<tr>
<td>NF1</td>
<td>Nonsense or Frameshift or Splice Site</td>
<td>&lt;5%</td>
<td>More frequent in CMML (5%–10%) and in JMML (30%) where it is often germline.</td>
</tr>
<tr>
<td>RUNX1</td>
<td>Nonsense or Frameshift</td>
<td>10%–15%</td>
<td>Independently associated with a poor prognosis in MDS. May be familial in very rare cases.</td>
</tr>
<tr>
<td>ETV6</td>
<td>Nonsense or Frameshift</td>
<td>&lt;5%</td>
<td>Independently associated with a poor prognosis. May be familial in very rare cases.</td>
</tr>
<tr>
<td>IDH1</td>
<td>Misssense: R132</td>
<td>&lt;5%</td>
<td>More frequent in AML.</td>
</tr>
<tr>
<td>IDH2</td>
<td>Misssense: R140Q, R172</td>
<td>&lt;5%</td>
<td>More frequent in AML. Associated with a poor prognosis.</td>
</tr>
<tr>
<td>SETBP1</td>
<td>Misssense: E858, T864, I865, D868, S869, G870</td>
<td>&lt;5%</td>
<td>Associated with disease progression. More frequent in CMML (5%–10%) and JMML (7%).</td>
</tr>
<tr>
<td>PHF6</td>
<td>Nonsense or Frameshift or Splice Site</td>
<td>&lt;5%</td>
<td>More frequent in cases with excess blasts, but no association with survival.</td>
</tr>
<tr>
<td>BCOA</td>
<td>Nonsense or Frameshift or Splice Site Misssense: in codon N1425</td>
<td>&lt;5%</td>
<td>Associated with a poor prognosis. More frequent in CMML (5%–10%).</td>
</tr>
<tr>
<td>STAT3</td>
<td>Misssense: any codons 584–674</td>
<td>&lt;5%</td>
<td>Occurs in large granular lymphocyte leukemia (LGL) associated with MDS; associated with immune bone marrow failure.</td>
</tr>
<tr>
<td>PPM1D</td>
<td>Nonsense or Frameshift</td>
<td>~5%</td>
<td>Associated with therapy-related MDS, but not associated with adverse prognosis independent of TP53.</td>
</tr>
</tbody>
</table>

1The specific mutations listed in this table are likely to be somatic if found in tumor material. Their absence in non-hematopoietic tissues would be required to prove that they are acquired. Several of the genes listed have congenital mutations that are disease-related in rare cases (eg, RUNX1, TP53, CBL). Known gene polymorphisms frequent in the population should be excluded from DNA sequencing results as they are likely germline variants and not evidence of clonal hematopoiesis.

2Somatic mutations in several MDS-associated genes (eg, TET2, DNMT3A, TP53) can occur in non-disease states and no gene mutation is diagnostic of MDS. Mutations in several genes can occur in neoplasms other than MDS, including lymphoid malignancies such as CLL and ALL. Mutations should not be used as presumptive evidence of MDS when diagnostic criteria for MDS have not been met.

Mutation type definitions: Nonsense – a mutation that changes an amino acid codon into a premature stop codon. Frameshift – the insertion or deletion of DNA base pairs that changes the amino acid reading frame. Misssense – a mutation that changes one amino acid codon into another (eg, K700E indicates that the lysine [K] at codon 700 was mutated to a glutamic acid [E]). If no new amino acid is specified for a codon in the table, then it may be mutated into one of several possible amino acids (eg, R882 indicates that the arginine [R] at position 882 can be mutated in more than one way).
Data for the table are derived from references listed below and are discussed in the following reviews:


Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. Note: All recommendations are category 2A unless otherwise indicated.

Discussion

GERMLINE MUTATIONS WITH PREDISPOSITION FOR MDS/AML/MPN: ESTABLISHED & EMERGING FAMILIAL SYNDROMES

<table>
<thead>
<tr>
<th>Affected Gene</th>
<th>Typical Age at Transformation</th>
<th>Potentially Associated Diseases or Syndromes</th>
<th>Clinical Phenotypes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Familial MDS/AML</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RUNX1</strong></td>
<td>Early to mid adulthood</td>
<td>Familial platelet disorder with predisposition to AML</td>
<td>Mild to moderate thrombocytopenia and/or platelet dysfunction prior to development of MDS/AML.</td>
</tr>
<tr>
<td><strong>GATA2</strong></td>
<td>Childhood to young adulthood</td>
<td>MonoMAC syndrome, Emberger syndrome, pulmonary alveolar proteinosis, hereditary lymphedema, congenital deafness, cutaneous warts</td>
<td>Immunodeficiency with marked susceptibility to EBV, HPV, and other viruses, atypical mycobacteria, and fungal infections. Transformation to MDS/AML is usually preceded by a period of bone marrow failure. Monosomy 7 and/or somatic ASXL1 mutations are often present at transformation.</td>
</tr>
<tr>
<td><strong>ETV6</strong></td>
<td>Childhood to young adulthood</td>
<td>Dysmorphic facial features and developmental delay. Increased risk for colon and skin cancers, myopathy, and autoimmune disorders.</td>
<td>Chronic thrombocytopenia typically precedes transformation. May transform to myeloid malignancy or acute lymphoblastic leukemia.</td>
</tr>
<tr>
<td><strong>CEBPA</strong></td>
<td>Early to mid adulthood</td>
<td>None described</td>
<td>Typically no chronic prodrome. Most often transforms to AML, typically acquiring a second CEBPA mutation. High penetrance. Relapses may represent second primary transformation events.</td>
</tr>
<tr>
<td><strong>DDX41</strong></td>
<td>Mid to late adulthood</td>
<td>Autoimmune disorders</td>
<td>Typically no chronic prodrome. May present as MDS or AML and may acquire second DDX41 mutation.</td>
</tr>
<tr>
<td><strong>ANKRD26</strong></td>
<td>Childhood to mid adulthood</td>
<td>Thrombocytopenia, leukocytosis</td>
<td>Moderate thrombocytopenia and/or platelet dysfunction. Dysmegakaryopoiesis is striking, and caution should be exercised before using this as the sole criteria for defining MDS in these patients.</td>
</tr>
<tr>
<td><strong>SRP72</strong></td>
<td>Unknown</td>
<td>Congenital sensorineural hearing loss</td>
<td>Bone marrow failure or aplasia may precede transformation.</td>
</tr>
</tbody>
</table>

Classical Inherited Bone Marrow Failure Syndromes

<table>
<thead>
<tr>
<th>Affected Gene</th>
<th>Typical Age at Transformation</th>
<th>Potentially Associated Diseases or Syndromes</th>
<th>Clinical Phenotypes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TERT/TERC</strong></td>
<td>Early to mid adulthood</td>
<td>Nail and skin changes, sensorineural deafness, cirrhosis, hereditary pulmonary fibrosis, emphysema, and signs of early aging (premature graying of hair). Increased risk for head and neck cancers, anogenital cancers, and skin cancer.</td>
<td>Transformation to MDS/AML is usually preceded by a period of bone marrow failure. Adult patients may not have any associated physical findings.</td>
</tr>
<tr>
<td><strong>FANC genes,</strong></td>
<td>Childhood to mid adulthood</td>
<td>Fanconi anemia, dyskeratosis congenita, or Shwachman-Diamond syndrome. Dysmorphic features, short stature, nail and skin changes, thumb hypoplasia, dysmorphic facial features, pulmonary fibrosis, neutropenia, exocrine pancreatic insufficiency.</td>
<td>Chronic bone marrow failure and aplastic anemia typically precede transformation to clonal neoplasms. Adult patients may not have any associated physical findings.</td>
</tr>
<tr>
<td><strong>DKC, SBDS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ELA2, HAX1,</strong></td>
<td>Childhood to early adulthood</td>
<td>Severe congenital neutropenia</td>
<td>Variable rates of transformation, often after prolonged G-CSF therapy for neutropenia.</td>
</tr>
<tr>
<td><strong>GFI1</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Other Inherited Syndromes Associated with MDS/AML/MPN

<table>
<thead>
<tr>
<th>Affected Gene</th>
<th>Typical Age at Transformation</th>
<th>Potentially Associated Diseases or Syndromes</th>
<th>Clinical Phenotypes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TP53</strong></td>
<td>Late childhood through adulthood</td>
<td>Li-Fraumeni syndrome. Increased risk of brain tumors, sarcomas, colon, and breast cancers among others.</td>
<td>Therapy-related neoplasms may emerge after treatment for solid tumors. Complex karyotypes are common as with somatic TP53 mutations.</td>
</tr>
<tr>
<td><strong>PTPN11, CBL,</strong></td>
<td>Infancy to early childhood</td>
<td>Noonan syndrome, neurofibromatosis</td>
<td>Typically presents as JMML.</td>
</tr>
<tr>
<td><strong>KRAS, NF1</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>BLM</strong></td>
<td>Infancy to early childhood</td>
<td>Bloom syndrome</td>
<td>Short stature, immunodeficiency, microcephaly, high-pitched voice, hypogonadism</td>
</tr>
<tr>
<td><strong>ATG2B/GSKIP</strong></td>
<td>Unknown</td>
<td>Myeloproliferative neoplasms</td>
<td>Typically no chronic prodrome. Can present with myeloproliferative/myelodysplastic overlap features or AML.</td>
</tr>
<tr>
<td><strong>BRCA1/BRCA2</strong></td>
<td>Adulthood</td>
<td>Increased risk for breast cancer, male breast cancer, ovarian cancer, prostate cancer, and pancreatic cancer among others.</td>
<td>Therapy-related neoplasms may emerge after treatment for solid tumors.</td>
</tr>
</tbody>
</table>

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
GERMLINE MUTATIONS WITH PREDISPOSITION FOR MDS/AML/MPN: ESTABLISHED & EMERGING FAMILIAL SYNDROMES

Notes:

• Germline mutations predisposing to myeloid malignancy can occur without family history either due to variable penetrance or spontaneous (de novo) mutation in the affected individual.
• Younger patients with MDS and those with therapy-related myeloid malignancies may be more likely to harbor germline variants in these predisposition genes.
• Older patients who harbor germline predisposition mutations as variants may have variable penetrance or longer latency for disease development, as seen with germline DDX41 mutations.
• Syndromic features ascribed to several of these germline mutations may not be present due to variable penetrance or hypomorphic variants with distinct associated phenotypes.
• Consider germline variants in patients when mutations in these genes are observed in tumor sequencing tests, especially when mutations are biallelic, as in biallelic CEBPA mutant AMLs.
• Whenever possible, genetic testing should be performed on constitutional tissue, preferably on skin fibroblasts, in order to exclude somatic mutations and to avoid false negatives due to peripheral blood somatic mosaicism.
• Clinicians can access www.genetests.org to find places to obtain CLIA-approved sequencing.

References:

1 Babushok DV, Bessler M, Olson TS. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults. Leukemia Lymphoma 2015;57(3):520-536.
**Spectrum of Indolent Myeloid Hematopoietic Disorders**

<table>
<thead>
<tr>
<th>Feature</th>
<th>ICUS</th>
<th>IDUS</th>
<th>CHIP</th>
<th>CCUS</th>
<th>MDS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Somatic mutation</td>
<td>-</td>
<td>-</td>
<td>+/-</td>
<td>+/-</td>
<td>+/-</td>
</tr>
<tr>
<td>Clonal karyotypic</td>
<td>-</td>
<td>-</td>
<td>+/-</td>
<td>+/-</td>
<td>+/-</td>
</tr>
<tr>
<td>abnormality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marrow dysplasia</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Cytopenia</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

ICUS, idiopathic cytopenia of unknown significance;  
IDUS, idiopathic dysplasia of unknown significance;  
CHIP, clonal hematopoiesis of indeterminate potential;  
CCUS, clonal cytopenia of unknown significance;  
MDS, myelodysplastic syndromes

1 Regular monitoring of blood counts in these patients should be instituted after evaluation as in MDS-1 (generally at least every 6 months).  
2 For patients with MDS, see MDS-3, MDS-4, and MDS-C.  
3 Has one or more of these (+) features: either has a clonal karyotypic abnormality (present in ≥2 metaphases) and/or a somatic mutation (present at >2% variant allele frequency). Evaluation of mutations should include sequencing or panels incorporating at least the 21 most frequently mutated MDS-related genes as noted on MDS-C. Somatic mutations in more rarely mutated genes can also provide evidence for CHIP or CCUS.

**References:**
Initial Evaluation See MDS-1

- FCM:
  - Consideration should be given to obtain FCM testing at initial evaluation of MDS to include antibody combinations to characterize blasts and to identify abnormal lymphoid populations (such as increased hematogones, which may mimic blasts, leading to erroneous myeloblast quantitation). For example, a combination using anti-CD45, -CD34, -CD33, and -CD19 (with forward scatter and side scatter) could be useful.
  - It is understood that the blast percent for both diagnosis and risk stratification should be determined by morphologic assessment, not solely by FCM. If blasts are increased and morphologic questions arise regarding their subtype (ie, myeloid or lymphoid), they should be characterized with a more elaborate panel of antibodies.
  - In diagnostically difficult cases, in expert hands, an expanded panel of antibodies to demonstrate abnormal differentiation patterns or aberrant antigen expression may help confirm diagnosis of MDS (See Initial Evaluation in the Discussion).
  - Flow cytometric abnormalities are often seen in MDS, and in some cases may correlate with observed morphologic abnormalities. They may also help diagnostically in patients with clinical suspicion of MDS who have no significant morphologic dysplasia and whose chromosome/FISH studies are either negative or normal.
  - FCM is most useful in detecting aberrant immature myeloid lineages often observed in myelodysplastic syndromes. Flow analysis will detect aberrant expression of B or T cell antigens on myeloid precursors, and selective loss or gain of additional markers (eg, loss or dim expression of CD33, CD34, CD56, CD38, or CD117) on myeloid precursors. Flow will help in cytopenia associated with LGL expansion by detecting increase of CD56/CD57+ cells. CMML-associated monocytic aberrancies can be easily detected by combination of CD64/CD14, and CD16 loss or dim expression. In addition, qualitative abnormalities in mature myeloid lineages, eg, hypogranular late myelocytes, bands/Pelger-Huet cells and neutrophils will have abnormal flow patterns (low or negative for CD16 or CD10). However, the erythroid lineage dysplasia (dyserythropoiesis) detection by FCM is limited due to variable RBC lysis methods used in preparing flow mononuclear cell suspension. Megakaryocytic dysplasia cannot be assessed in FCM.


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
Discussion

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise indicated.

Table of Contents

Overview ................................................................................................. MS-2
Literature Search Criteria and Guidelines Update Methodology .......... MS-2
Diagnostic Classification.......................................................................... MS-3
  Myelodysplastic Syndromes ................................................................. MS-3
  Myelodysplastic/Myeloproliferative Neoplasms ................................. MS-5
  Indolent Myeloid Hematopoietic Disorders .......................................... MS-6
  Pediatric MDS...................................................................................... MS-7
Evaluation ............................................................................................... MS-9
  Initial Evaluation ................................................................................ MS-9
  Additional Testing .............................................................................. MS-10
  Evaluation of Related Anemia ............................................................ MS-13
Prognostic Stratification........................................................................... MS-14
  Prognostic Scoring Systems................................................................. MS-14
    IPSS ............................................................................................ MS-14
    WPSS ........................................................................................ MS-15
    IPSS-R ...................................................................................... MS-15
    LR-PSS...................................................................................... MS-17
Molecular Abnormalities in MDS.......................................................... MS-18
Comorbidity Indices ............................................................................. MS-19
Therapeutic Options ............................................................................. MS-19
  Supportive Care .............................................................................. MS-20
    Management of Thrombocytopenia .............................................. MS-21
    Management of Iron Overload ...................................................... MS-22
    Treatment of Related Anemia ....................................................... MS-24
  Low-Intensity Therapy ..................................................................... MS-26
    Hypomethylating Agents .............................................................. MS-26
    Biologic Response Modifiers and Immunosuppressive Therapy .... MS-28
  High-Intensity Therapy ................................................................... MS-31
Recommended Treatment Approaches ................................................... MS-32
  Therapy for Lower-Risk Patients (IPSS Low, Intermediate-1; IPSS-R Very Low, Low, Intermediate; or WPSS Very Low, Low, Intermediate)...... MS-32
  Therapy for Higher-Risk Patients (IPSS Intermediate-2, High; IPSS-R Intermediate, High, Very High; or WPSS High, Very High)............. MS-33
  Intensive Therapy .......................................................................... MS-34
  Non-Intensive Therapy .................................................................. MS-35
Supportive Care Only .......................................................................... MS-35
Summary ............................................................................................... MS-35
References ............................................................................................ MS-37
Overview
The myelodysplastic syndromes (MDS) represent myeloid clonal hemopathies with a relatively heterogeneous spectrum of presentation. The major clinical problems in these disorders are morbidities caused by cytopenias and the potential for MDS to evolve into acute myeloid leukemia (AML). In the general population, the incidence rate of MDS is approximately 4.9 per 100,000 people per year.\(^1\) MDS is rare among children/adolescents and young adults, with an incidence rate of 0.1 per 100,000 people per year in those younger than 40 years of age. However, among individuals between the ages of 70 and 79 years, the incidence rate increases to 30.2 per 100,000 people, and further to 59.8 per 100,000 people among those 80 years of age and older.\(^1\)

The management of MDS is complicated by the generally advanced age of the patients (median age at diagnosis, 70–75 years),\(^2\) the attendant non-hematologic comorbidities, and the relative inability of older patients to tolerate certain intensive forms of therapy. In addition, when the illness progresses into AML, these patients experience lower response rates to standard therapy than patients with de novo AML.\(^3\)

The multidisciplinary panel of MDS experts for the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) meets annually to update recommendations on standard approaches to the diagnosis and treatment of MDS in adults. These recommendations are based on a review of recent clinical evidence that has led to important advances in treatment or has yielded new information on biological factors that may have prognostic significance in MDS.

Literature Search Criteria and Guidelines Update Methodology
Prior to the update of this version of the NCCN Guidelines® for Myelodysplastic Syndromes, an electronic search of the PubMed database was performed to obtain key literature using the following search term: myelodysplastic syndromes. The PubMed database was chosen as it remains the most widely used resource for medical literature and indexes only peer-reviewed biomedical literature.\(^4\)

The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase I; Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; Guideline; Meta-Analysis; Randomized Controlled Trial; Systematic Reviews; and Validation Studies.

The PubMed search resulted in 12 citations and their potential relevance was examined. The data from key PubMed articles as well as articles from additional sources deemed as relevant to these Guidelines and discussed by the panel have been included in this version of the Discussion section (eg, e-publications ahead of print, meeting abstracts) since the Guidelines were last published. Recommendations for which high-level evidence is lacking are based on the panel’s review of lower-level evidence and expert opinion.

The complete details of the Development and Update of the NCCN Guidelines are available on the NCCN webpage.
Diagnostic Classification

Myelodysplastic Syndromes

The initial evaluation of patients with suspected MDS requires careful assessment of the peripheral blood smear and blood counts, marrow morphology, cytogenetics, duration of abnormal blood counts, other potential causes of cytopenias, and concomitant illnesses. To establish the diagnosis of MDS, careful morphologic review and correlation with the patient’s clinical features are important, because a number of medications and viral infections (including HIV infection) can cause morphologic changes in marrow cells that are similar to MDS.3,5 The NCCN Guidelines for Myelodysplastic Syndromes include the WHO 2016 classification system for diagnostic evaluations.

To assist in providing consistency in the diagnostic guidelines for MDS, an International Consensus Working Group recommended that minimal diagnostic criteria for this disease include two prerequisites: stable cytopenia (for at least 6 months unless accompanied by a specific karyotype or bilineage dysplasia, in which case only 2 months of stable cytopenias are needed) and the exclusion of other potential disorders as a primary reason for dysplasia or cytopenia or both. In addition, the diagnosis of MDS requires at least one of three MDS-related (decisive) criteria: 1) dysplasia (≥10% in one or more of the three major bone marrow lineages); 2) a blast cell count of 5% to 19%; and 3) a specific MDS-associated karyotype [eg, del(5q), del(20q), +8, or -7/del(7q)]. Furthermore, several co-criteria may help confirm the diagnosis of MDS. These co-criteria include aberrant immunophenotype by flow cytometry, abnormal bone marrow histology and immunohistochemistry, or the presence of molecular markers (ie, abnormal CD34 antigen expression, fibrosis, dysplastic megakaryocytes, atypical localization of immature progenitors, myeloid clonality).6

Consistent with these recommendations, as stated by WHO, the features that are central for the diagnosis of MDS entail well-defined dysplasia in one or more hematopoietic cell lines in addition to cytopenias. Cytopenias need to be persistent (for at least 4–6 months) and lack other underlying conditions serving as a primary cause of the cytopenia.7 Further, analyses of studies including the MDS databases, which generated the International Prognostic Scoring System (IPSS) and Revised IPSS (IPSS-R), have shown that the use of standard hematologic values to define cytopenic cut points for MDS diagnosis are more appropriate than the WHO-recommended prognostic cytopenia cut points.8

In 2001, WHO proposed an alternative classification for MDS that was modified from the original French-American-British (FAB) definitions.9-11 Since then, the WHO classification has been updated twice, once in 2008 and again in 2016. The current WHO guidelines identify six entities of MDS: MDS with single lineage dysplasia (MDS-SLD); MDS with ring sideroblasts (MDS-RS); MDS with multilineage dysplasia (MDS-MLD); MDS with excess blasts (MDS-EB); MDS with isolated del(5q); and MDS unclassifiable (MDS-U) (see 2016 WHO Classification of MDS and Myelodysplastic/Myeloproliferative Neoplasms in the algorithm). There is an additional provisional entity termed “refractory cytopenia of childhood” (RCC). MDS-SLD includes refractory anemia (RA; unilineage erythroid dysplasia), refractory neutropenia (unilineage dysgranulopoiesis), and refractory thrombocytopenia (unilineage dysmegakaryocytopoiesis). The latter two were previously classified as MDS-U in 2001 but were reclassified in the 2008 update.12

A review article discusses the major changes and the rationale behind the revisions in the 2016 WHO classification of MDS and AML evolving from MDS.13 The 2016 WHO classification stratifies MDS-RS based on
single lineage dysplasia (MDS-RS-SLD) and multilineage dysplasia (MDS-RS-MLD). The presence of the SF3B1 mutation is associated with the presence of ring sideroblasts. The updated WHO classification expanded the definition of MDS-RS to include patients who have the SF3B1 mutation but lack excess blasts or an isolated del(5q) abnormality. MDS-EB cases are separated into those with less than 10% marrow blasts (MDS-EB-1) and those with 10% to 19% marrow blasts (MDS-EB-2). It should also be noted that the denominator used for determining blast percentage in all myeloid neoplasms was redefined to include all nucleated bone marrow cells as opposed to only nonerythroid cells. This modification will shift a select group of patients who were previously categorized as “AML, not otherwise specified” (the specific subentity was M6 AML [erythroleukemia]) to “MDS-EB.”

The del(5q) entity is defined by the presence of this deletion and can include one additional cytogenetic abnormality, with the exception of monosomy 7 or del(7q), which is associated with poor outcomes. The modification of this definition stemmed from data that showed a prognostic stratification among patients with del(5q) based on the number of additional cytogenetic abnormalities compared to the single mutation del(5q). Due to low reproducibility, another change in the 2016 update includes the requirement for 1% blasts in the peripheral blood on two separate occasions prior to diagnosing MDS-U.

The division between MDS and AML is a continued area of debate. The original FAB definition of MDS included patients with up to 30% blasts. The 2001 WHO classification reduced the upper limit for blast percentage for MDS to 19%, rather than the previous cut-off of 29%, thereby reclassifying these patients as “AML with myelodysplasia-related changes.” It was noted in the 2008 WHO classification that some patients with AML with myelodysplasia-related changes who have 20% to 29% marrow blasts may behave in a manner more similar to MDS than to AML. Data suggest that these patients have less aggressive disease and improved outcomes and therapeutic responses compared to patients with greater than 30% blasts and should be considered a favorable group of AML. The NCCN Panel recognizes that MDS are not only related to blast quantitation, but they also possess a differing pace of disease related to distinctive biologic features when compared with de novo AML. Therefore, the NCCN Panel classifies patients who have 20% to 29% marrow blasts as “MDS-EB in transformation (MDS-EB-T),” a term carried over from the originally FAB classification. The MDS Panel recommends using the WHO classification with the qualifier that the MDS-EB-T patient subgroup be considered as either MDS or AML. As indicated in the algorithm (see MDS-A 1 of 2), the NCCN Guidelines allow for patients with 20% to 29% blasts AND a stable clinical course for at least 2 months to be considered as having either MDS or AML. Individuals with FLT3 and NPM1 mutations are more likely to have AML than MDS. The decision to treat these patients with intensive AML therapy is complex and should be individualized. Patients who have previously been included in and benefitted from therapeutic trials for MDS should continue to be eligible for MDS-type therapy. The clinician should consider such factors as age, antecedent factors, cytogenetics, comorbidities, pace of disease, performance status, and the patient’s goal of treatment. This recommendation is further supported by the results from several validation studies and analyses.

The WHO classifications are revised to improve both the diagnostic and prognostic capabilities of these entities. MDS with del(5q) generally has a relatively good prognosis and is highly responsive to lenalidomide therapy. With a moderate degree of variability, MDS-EB and MDS-EB-T patients generally have a relatively poor prognosis, with a median survival ranging from 5 to 12 months. In contrast, MDS-RS-SLD (RA) or
MDS-RS patients have a median survival of approximately 3 to 6 years. The proportion of these individuals with disease that transforms to AML ranges from 5% to 15% in the low-risk MDS-RS-SLD/MDS-RS group to 40% to 50% in the relatively high-risk MDS-EB/MDS-EB-T group. In a study evaluating time-to-disease evolution, 25% of MDS-EB cases and 55% of MDS-EB-T cases underwent transformation to AML in the first year, increasing to 35% of MDS-EB cases and 65% of MDS-EB-T cases within 2 years. In contrast, the incidence of transformation for RA was 5% in the first year and 10% within 2 years. None of the MDS-RS patients developed leukemia within 2 years.

Biologic evidence indicates that similar clinical phenotypes, including lower blast counts, older age, lower white blood cell (WBC) counts, and higher erythroblast counts in bone marrow, are seen in patients with splicing factor (SF) mutations among the MDS-EB, MDS-EB-T, and some AML categories compared with SF-non-mutated cases. This suggests that SF-mutated cases comprised a distinct entity among MDS/AML and that SF-mutant MDS-EB/MDS-EB-T constitutes a related disorder overriding the artificial separation between AML and MDS. AML evolving from MDS (AML-MDS) is often more resistant to standard cytotoxic chemotherapy than de novo AML, especially those AML cases that do not have TP53 mutations nor those typical of secondary MDS, which arises without a known antecedent hematologic disorder. High-risk MDS, AML-MDS, and some elderly patients with AML may have a more indolent clinical course in terms of short-term progression compared with patients who have standard presentations of de novo AML. This emphasizes the need to treat at least some patients with a standard presentation of de novo AML differently than patients with indolent MDS (see NCCN Guidelines for Acute Myeloid Leukemia).

Myelodysplastic/Myeloproliferative Neoplasms

The category of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) was added to the 2008 update of the WHO classification of myeloid neoplasms. This category includes chronic myelomonocytic leukemia (CML); atypical chronic myeloid leukemia (aCML), BCR-ABL1 negative; and juvenile myelomonocytic leukemia (JMML) as disorders having overlapping dysplastic and proliferative features. The MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and the MDS/MPN unclassifiable groups are also included in this category. See 2016 WHO Classification of MDS and Myelodysplastic/Myeloproliferative Neoplasms in the algorithm.

CMML has been subdivided into two groups based on molecular and clinical differences: proliferative-type CMML (WBC count ≥13 x 10⁹/L) and dysplastic type CMML (WBC < 13 x 10⁹/L). In addition to the WBC count, the percentage of blasts plus monocytes in the peripheral blood and bone marrow has demonstrated prognostic significance. Three blast-based groups have been created in the 2016 classification (previously only two groups were identified) and are defined as follows: CMML-0, for patients with less than 2% peripheral blood blasts and less than 5% bone marrow blasts; CMML-1 for patients with 2% to 4% peripheral blood blasts and/or 5% to 9% bone marrow blasts; and CMML-2 for patients with 5% to 19% peripheral blood blasts, 10% to 19% bone marrow blasts, and/or the presence of Auer rods (see 2016 WHO Classification of MDS and Myelodysplastic/Myeloproliferative Neoplasms in the algorithm).

The second subtype, aCML, is rare and has similar neutrophilia as the chronic neutrophilic leukemia (CNL) subtype of MPN. However, molecular characterization may distinguish the two entities. The presence of CSF3R mutations is strongly associated with CNL but is
present in less than 10% of aCML cases. Other MPN-associated driver mutations (ie, JAK2, CALR, MPL) are uncommon in aCML. The presence of SETBP1 or ETNK1 mutations (or both) is reported in up to a third of aCML patients.

JMML is a rare childhood cancer that presents in infants and young children. Clinical and hematologic criteria for the diagnosis of JMML include: peripheral blood monocyte count equal to or greater than 1 x 10³/L; blast percentage in the peripheral blood and bone marrow less than 20%; splenomegaly; and the absence of BCR/ABL1 rearrangement. Although there are no mutations that are exclusive to this disease subtype, the most frequently mutated genes in JMML are PTPN11 (40%–50%), NRAS (15%–20%), KRAS (10%–15%), CBL (15%–18%), and NF1 (10%–15%). In some patients, these mutations may be present as germline variants where they are frequently associated with Noonan syndrome or other congenital syndromes (see Frequent Mutations in MDS-Associated Genes Likely to Indicate Clonal Hematopoiesis in the algorithm). In patients who do not have genetic features of JMML, monosomy 7 or any other chromosomal abnormality must be present with at least two of the following: hemoglobin F increased for age; myeloid or erythroid precursors on peripheral blood smear; granulocyte-macrophage colony-stimulating factor (GM-CSF) hypersensitivity in colony assay; and hyperphosphorylation of STAT5.

MDS-RS-T includes cases that present with clinical and morphologic features consistent with MDS and thrombocytosis (platelet counts ≥450 x 10³/L). The morphology of MDS-RS-T is characterized by MDS-RS features (no blasts in the peripheral blood, dysplastic erythroid proliferation, ring sideroblasts ≥15% of erythroid precursors, and <5% blasts in marrow) with proliferation of large atypical megakaryocytes similar to those seen in essential thrombocythemia or primary myelofibrosis. The frequency of spliceosome gene SF3B1 mutations in up to 60% of MDS-RS-T cases has resulted in the inclusion of MDS/MPN-RS-T as a full entity. SF3B1 mutations are associated with the presence of ring sideroblasts and frequently have the JAK2 V617F mutation or MPL W515K/L mutation. In contrast to MDS-RS, SF3B1 mutations do not change the required percentage of ring sideroblasts for diagnostic classification.

Indolent Myeloid Hematopoietic Disorders

The spectrum of indolent myeloid hematopoietic disorders encompasses four groups: idiopathic cytopenia of undetermined significance (ICUS); idiopathic dysplasia of unknown significance (IDUS); clonal hematopoiesis of indeterminate potential (CHIP); and clonal cytopenia of undetermined significance (CCUS). Based on somatic mutation, clonal karyotypic abnormality, marrow dysplasia, and cytopenia features, patients can be classified within the spectrum (see Spectrum of Indolent Myeloid Hematopoietic Disorders in the algorithm). These disorders can evolve into MDS or AML, though the frequency of progression may differ among the four groups.

CHIP and CCUS are defined by the presence of a clonal karyotypic abnormality (present in ≥2 metaphases) and/or a somatic mutation in a gene involved in hematopoiesis (present at >2% variant allele frequency). There is an absence of marrow dysplasia in these patients. CCUS differs from CHIP by having the presence of cytopenia. Although CHIP is generally benign and has a low likelihood of progression compared to other pre-malignant conditions, there is a higher risk of subsequent hematologic disease compared to patients who do not have somatic mutations. Additionally, shorter survival in these patients compared with age-matched controls has been demonstrated and may be attributed to non-hematologic causes. ICUS and IDUS have no known cause, lack somatic mutations or clonal karyotypic abnormalities,
and differ from each other only by the presence of cytopenia or marrow dysplasia, respectively. There is significant heterogeneity within ICUS, with some patients experiencing spontaneous resolution of disease and others developing a myeloid neoplasm. Data are limited regarding natural history and disease progression for these two disorders.

Two recent studies have focused on the role of mutational analysis in indolent malignant disease. In a prospective analysis of 144 patients, Kwok and colleagues utilized a 22-gene panel to determine the frequency of MDS-associated mutations. Among these patients, 17% were categorized as MDS, 15% as ICUS with mild dysplasia, and 69% as ICUS without dysplasia. Further analysis showed that 35% of ICUS patients had a somatic mutation or chromosomal abnormality similar to MDS; these patients were characterized as CCUS. The similar mutational features may have a role in the diagnostic value of these disorders.

Cargo et al evaluated mutational features associated with ICUS in patients with disease that developed into progressive dysplasia or AML. Although this study was not designed to evaluate the diagnostic role of mutations, detection of mutational features predicted progression to high-risk disease and overall survival (OS). The study proposes that patients who are defined as poor-risk may benefit from early intervention.

NCCN recommends that following the initial evaluation, regular monitoring of blood counts in patients with these indolent myeloid hematopoietic disorders occurs at least every 6 months. More frequent monitoring may be recommended based on clinical expertise.

### Pediatric MDS

Several differences exist between adult and childhood myelodysplasia. MDS and myelodysplasia are quite rare in children, occurring in 1 to 4 cases per million per year with a median age of 6.8 years. MDS in children is strongly associated with congenital disorders. Genetic syndromes are evident in 50% of cases, including Down syndrome, trisomy 8 syndrome, Fanconi anemia, congenital neutropenia (Kostmann syndrome), Diamond-Blackfan anemia, Shwachman-Diamond syndrome, dyskeratosis congenita (DC), neurofibromatosis type 1, Bloom syndrome, Noonan syndrome, and Dubowitz syndrome. Prior exposure to cytotoxic therapy (eg, alkylating agents, epipodophyllotoxins, topoisomerase II inhibitors) or radiation increases the risk for MDS.

The 2008 WHO classification separates pediatric myeloproliferative diseases (MPDs) into three groups: MDS (RCC, MDS-EB, MDS-EB-T, or AML with MDS-related changes); myelodysplastic/myeloproliferative disease (JMML); and Down syndrome disease (transient abnormal myelopoiesis and myeloid leukemia of Down syndrome). RCC is the most common subtype of MDS found in children, accounting for approximately 50% of cases. Abnormal karyotypes are found in 30% to 50% of children with MDS; most common are numerical anomalies with less than 10% showing structural abnormalities. Monosomy 7 is the most common cytogenetic abnormality, occurring in 30% of cases, followed by trisomy 8 and trisomy 21. The del(5q) abnormality is rarely seen in children. Clinically, isolated RAs are uncommon in children. Thrombocytopenia and/or neutropenia, often accompanied by hypocellular marrow, is a common presentation. Fetal hemoglobin levels are frequently elevated.
Differential diagnoses include aplastic anemia (AA) and AML. Compared to AA, children with MDS have a significantly elevated mean corpuscular volume; clonal hematopoiesis is confirmatory. Higher expression of \( p53 \), lower expression of survivin, or the presence MDS-related cytogenetic abnormalities can also help differentiate MDS from AA. Compared with AML, low WBC count, multi-lineage dysplasia, and clonal hematopoiesis with numerical, rather than structural, cytogenetic abnormalities suggest MDS. A bone marrow blast count of less than 20% also suggests MDS, but biological features are more important than a strict cut-off value. Monosomy 7 strongly suggests MDS. When patients present with AML, the marrow frequently shows dysplastic features, but this does not necessarily indicate that the AML arose after MDS. Indeed, criteria for the diagnosis of MDS in a patient who presents with AML are stringent. Dysplasia in bone marrow cells may also be due to other etiologies including infection (eg, Parvo virus, herpes viruses, HIV), deficiencies of B12 and copper, drug therapy, and chronic disease. Congenital dyserythropoietic anemia, congenital sideroblastic anemia, and Pearson syndrome should also be excluded.

Children with Down syndrome have an increased risk for developing leukemia (50-fold greater risk if younger than 5 years old), and are usually categorized as having acute megakaryoblastic leukemia (AMKL, M7). This commonly has a prodromal phase of cytopenia(s) similar to MDS and may be considered a spectrum of the same disease. Prognosis of patients with Down syndrome and AMKL is quite good with an 80% cure rate when treated with intensive chemotherapy. Hematopoietic cell transplantation (HCT) is not indicated in first complete remission for these children. Newborns with Down syndrome can develop abnormal myelopoiesis with leukocytosis, circulating blasts, anemia, and thrombocytopenia, but this resolves spontaneously within weeks to months. Approximately 20% of children with Down syndrome, who have transient abnormal myelopoiesis, will subsequently develop AMKL.

There is a paucity of clinical trials due to the rarity and heterogeneity of MDS in children. The primary goal of treatment is generally a cure rather than palliation. HCT is the only curative option in childhood MDS with 3-year disease-free survival rates of approximately 50%. Myeloablative therapy with busulfan, cyclophosphamide, and melphalan, followed by either matched family or matched unrelated donor allogeneic HCT is the treatment of choice for children with MDS. Other treatments such as chemotherapy, growth factors, and immunosuppressive therapy (IST) have a limited role. Prognosis for untreated MDS depends on the rate of progression to AML. The stage of the disease at the time of HCT strongly predicts outcome.

Patients with RCC have a median time to progression to advanced MDS of 1.7 years, but the time to progression is highly variable, depending on the underlying cause of MDS and standard prognostic factors. Patients with JMML have a variable prognosis; some younger patients with favorable genetics and clinical features have resolution of JMML without treatment, while others progress rapidly despite allogeneic HCT. Children diagnosed before the age of 2 years have the best prognosis. Poor prognostic features include high hemoglobin F, older age, and thrombocytopenia.

Pediatric AML or MDS with monosomy 7 has a poor prognosis with conventional therapies. A recent review of 16 patients with AML and MDS with monosomy 7 treated by two transplant programs from 1992 to 2003 (MDS, \( n = 5 \); therapy-related MDS [t-MDS], \( n = 3 \); AML, \( n = 5 \); therapy-related AML [t-AML], \( n = 3 \)) reported a 2-year event-free survival of 69%. Four of the 5 deaths occurred in patients
transplanted with active leukemia. Seven of 8 MDS patients were alive without evidence of disease (6 in first complete remission, 1 in second complete remission, and 1 death due to complications).93

Although MDS cases can occur in both the adult and pediatric populations, the treatment strategies and recommendations are not necessarily the same. The NCCN Guidelines for Myelodysplastic Syndromes focus on recommendations for the diagnosis, evaluation, and treatment of adult patients with MDS; therefore, the discussions that follow pertain to adult patients.

**Evaluation**

Several types of evaluations are needed to determine the clinical status of patients with MDS. Understanding clinical status is necessary for diagnostic and prognostic categorization and to determine treatment options.

**Initial Evaluation**

Clinical history should include the timing, severity, and tempo of abnormal cytopenias; prior infections or bleeding episodes; and number of transfusions. Cytopenias are defined as values lower than standard laboratory hematologic levels, being aware of age, sex, ethnic, and altitude norms.8 Concomitant medications and comorbid conditions require careful assessment. Because MDS are relatively indolent disorders, blood count stability is used to distinguish MDS from evolving AML. Other possible causes of cytopenias require careful evaluation.

In addition to establishing current blood and reticulocyte counts, clinicians need a peripheral blood smear evaluation to determine the degree of dysplasia and, thus, potentially dysfunctional cells. Bone marrow aspiration with Prussian blue stain for iron and a biopsy are needed to evaluate the degree and relative proportions of hematopoietic cell maturation abnormalities, percentage of marrow blasts, marrow cellularity, presence or absence of ring sideroblasts (and presence of iron per se), and fibrosis. Cytogenetics for bone marrow samples (by standard karyotyping methods) should be obtained, because they are of major prognostic importance. If standard cytogenetics with 20 or more metaphases cannot be obtained, then an MDS-related fluorescence in situ hybridization (FISH) panel should be performed.

Other useful laboratory screening tests include serum erythropoietin (sEpo), vitamin B₁₂, red blood cell (RBC) folate levels, serum ferritin, iron, and total iron-binding capacity (TIBC). RBC folate and serum folate levels should not be considered equivalent, and RBC folate is preferred. RBC folate levels are more indicative of folate stores, whereas serum folate levels are reflective of recent nutrition. However, if RBC folate cannot be evaluated, serum folate should be considered as an alternative, though clinicians should be advised of the limitations. Serum ferritin levels may be nonspecific, particularly in the face of inflammatory conditions such as rheumatoid arthritis. In such cases, obtaining the serum iron levels and TIBC along with serum ferritin may be helpful. As hypothyroidism and other thyroid disorders can lead to anemia, patients should also be evaluated for levels of thyroid-stimulating hormone.94 HIV testing should also be performed, if clinically indicated.

Elevated levels of lactate dehydrogenase (LDH) are predictive of a decreased survival. LDH is a measure of the systemic inflammation that occurs as a result of tissue turnover or hemolysis. The IPSS and IPSS-R identified LDH as a prognostic feature and other studies have supported the association. In a retrospective study, LDH levels taken at diagnosis were stratified in patients categorized as IPSS-R intermediate. Patients with LDH levels equal to or higher than 320 U/L
Myelodysplastic Syndromes

(n = 8) had a significantly shorter overall OS than patients with levels below 320 U/L (n = 28; 347 days vs. 1339 days, respectively; \( P = .03 \)).

There have been reports that copper deficiency can mimic many of the peripheral blood and marrow findings seen in MDS. Copper deficiency is an etiology of anemia, neutropenia, and bone marrow dysplasia that may be under-recognized. There are rare patients with clinical presentation consistent with MDS that may be deficient in copper and for whom copper supplementation may resolve hematologic abnormalities. Copper and ceruloplasmin level assessments should be considered as part of the initial diagnostic workup in patients suspected of having low-risk MDS, especially those with gastrointestinal (GI) disorders and neuropathy. Clinical features associated with copper deficiency include vacuolation of myeloid and/or erythroid precursors, prior GI surgery, a history of vitamin B12 deficiency, severe malnutrition, and a history of zinc supplementation.

Additional Testing

If patients require platelet transfusions for severe thrombocytopenia, human leukocyte antigen (HLA) typing (A and B) may be helpful. For HCT candidates, cytomegalovirus (CMV) status and full HLA typing (A, B, C, DR, and DQ) of the patient and potential donors are needed. Flow cytometry for assessing the percentage of blast cells in the bone marrow (as measured by the expression of CD34 on the cell surface) may also be valuable in some clinical situations, including detection of large granular lymphocyte (LGL) disease. It should be emphasized, however, that estimates of blast percentage by flow cytometry do not provide the same prognostic information as the blast percentage derived from morphologic evaluation. Accordingly, flow cytometry data should not be used in lieu of the determination of morphologic blast percentage by an experienced hematopathologist.

The screening for paroxysmal nocturnal hemoglobinuria (PNH) or STAT-3 mutant cytotoxic T-cell clones is potentially useful for determining which patients may be more responsive to IST, particularly young patients with normal cytogenetics and hypoplastic MDS (see Prognostic Stratification). PNH is a rare acquired disorder of the blood arising from mutations in the PIGA gene resulting in defective synthesis of the glycosphatidylinositol (GPI) anchor. This, in turn, leads to a deficiency of proteins that are normally linked to the cell membrane of blood cells via a GPI anchor. Deficiency in GPI-anchored proteins such as those involved in complement inhibition (eg, CD55, CD59) leads to complement sensitivity of RBCs and subsequent hemolysis. Flow cytometry is the established method for detecting GPI-anchor–deficient cells for the diagnosis of PNH. Fluorescent aerolysin (FLAER), a protein that specifically binds to GPI anchors, has been shown to be a highly specific and reliable marker for detecting GPI-anchor–deficient clones among granulocytes or monocytes. For evaluation of PNH clonogenicity, it is recommended that multiparameter flow cytometry analysis of granulocytes and monocytes using FLAER, and at least one GPI-anchored protein, be conducted. It should be emphasized that although evidence of a minor PNH clone may be present in about 20% of patients with MDS, there is usually no evidence of PNH-related hemolysis in these patients.

Cases of patients with myelodysplastic features and clonal expansion of LGLs have been reported. In one of these studies, 3 out of 9 patients responded to IST as indicated by improved blood counts. Although patients with both MDS and LGL did not respond as well as LGL patients (33% vs. 66%; \( P = .01 \)), the presence of the T-cell clone may reflect a target for IST. A second study reported improved outcomes in 61 MDS patients with LGL clonogenicity receiving IST.
anti-thymocyte globulin (ATG). Moreover, the MDS-SLD RA subtype was determined as a favorable predictor of response compared to non-MDS-SLD RA patients (odds ratio [OR], 0.15; 95% CI, 0.04–0.59; \( P = .005 \)).

Bone marrow biopsy staining for reticulin is helpful for evaluating the presence and degree of bone marrow fibrosis. Increased reticulin fibers in the marrow at diagnosis are seen in approximately 5% to 10% of MDS cases. MDS with fibrosis is not considered a distinct subtype of MDS but rather is relegated to the unclassifiable category in the most recent WHO classification. These patients frequently present with severe pancytopenia; decreased survival in these patients has been reported.

In addition to basic flow cytometric evaluation at presentation for characterization of blasts and evaluation of lymphoid populations, expanded flow cytometry may be a useful adjunct for diagnosis of MDS in difficult cases. In expert hands (both in terms of technical sophistication and interpretation), flow cytometry may demonstrate abnormal differentiation patterns or aberrant antigen expression in myeloid or progenitor cells, which may help confirm a diagnosis of MDS, exclude differential diagnostic possibilities, and, in some patients, provide prognostic information. Flow analysis should use appropriate antibody combinations with four fluorescence channel instrumentation. Multiple aberrancies should be present for the diagnosis of MDS, as single aberrancies are not infrequent in normal populations. For follow-up studies, antibody combinations may be tailored to detect specific abnormalities implicated in the initial evaluation. While aberrancies have also been described in erythroid cells, most flow cytometry laboratories do not provide erythroid analysis.

The European LeukemiaNET developed a flow cytometric score based on the reproducible parameters of CD34 and CD45 markers to aid in the diagnosis of MDS. The scoring system was developed using multicenter retrospective data from patients with low-grade MDS (defined as <5% marrow blasts; \( n = 417 \)) and patients with non-clonal cytopenias as controls (\( n = 380 \)). This patient population was selected because low-grade MDS often lack specific diagnostic markers (eg, ring sideroblasts, clonal cytogenetic abnormalities), which makes it difficult to diagnose based on morphology alone. Bone marrow samples from patients with MDS compared with samples from patients with non-clonal cytopenias showed different flow cytometric patterns, including: 1) increased CD34+ myeloblast-related cluster size (defined by a wider distribution of CD45 expression and greater side scatter characteristics [SSC]); 2) decreased CD34+ B-progenitor cluster size (defined by a relatively low CD45 expression and low SSC); 3) aberrant myeloblast CD45 expression (based on the lymphocyte to myeloblast CD45 ratio); and 4) a decreased granulocyte SSC value (based on the granulocyte to lymphocyte SSC ratio). These four parameters were included in a logistic regression model, and a weighted score (derived from regression coefficients) was assigned to each parameter. The sum of the scores provided the overall flow cytometric score for each sample, with a score of 2 or higher defined as the threshold for MDS diagnosis. Using this flow cytometric score in the learning cohort, a correct diagnosis of MDS was made with 70% sensitivity and 93% specificity. Among MDS patients without specific markers of dysplasia, 65% were correctly identified. The positive predictive and negative predictive values were 92% and 74%, respectively. These outcomes were confirmed in the validation cohort, which showed 69% sensitivity and 92% specificity. This flow cytometric scoring system demonstrated a high diagnostic power in differentiating low-grade MDS from non-clonal cytopenias, and may be particularly useful in
establishing a diagnosis in situations where traditional diagnostic methods are indeterminate. Further independent validation studies are warranted to determine the utility of this method.

Because of the associated expense, the requirement for both technical and interpretational expertise, and the need for greater consensus on specific antibody combinations and procedures that are most informative and cost effective, flow cytometric assays should be performed by experienced laboratories, and used in general practice only when diagnosis is uncertain with traditional approaches (eg, blood counts, morphology, cytogenetics, increased blasts). Flow cytometry studies may also be used to assess the possibility of LGL disease, as indicated by LGLs present in the peripheral blood. In addition, STAT3 mutations are commonly found in T-LGL disease. Additional genetic screening should be considered for patients with familial cytopenias. Potentially associated diseases or syndromes may include Fanconi anemia, DC, Noonan syndrome, Bloom syndrome, and Li-Fraumeni syndrome (see *Germline Mutations with Predisposition for MDS/AML/MPN: Established & Emerging Familial Syndromes* in the algorithm). Shortened telomere length has been associated with diseases of bone marrow failure, including inherited disorders such as DC, particularly in the presence of mutations in the *DKC1*, *TERT*, or *TERC* genes that encode for components of the telomere complex. Telomere length can be measured by FISH assays using leukocyte (or leukocyte subset) samples. Other genetic lesions, such as those occurring in the *RUNX1* or *GATA2* gene, have been implicated in familial cases of MDS and other myeloid malignancies. Lesions within the *RUNX1* gene (mutations, deletions, or translocations) have been identified as one cause of a relatively rare autosomal-dominant familial platelet disorder that predisposes these patients to myeloid malignancies. In affected families with the *RUNX1* lesions, the incidence of MDS/AML is high, ranging from 20% to 60% in which the median age of onset is 33 years. This familial platelet disorder is characterized by the presence of thrombocytopenia, and a tendency for mild-to-moderate bleeding generally presents from childhood; however, some affected individuals may not display these clinical characteristics. Different types of genetic lesions in *RUNX1* account for the variable phenotypes associated with familial platelet disorder between different families. Cryptic genetic lesions in *RUNX1* have been reported in some patients with Fanconi anemia and MDS/AML. Identification of Fanconi anemia is clinically important, because it is associated with chromosomal fragility that results in variability of disease response to hypomethylating agents.

The *GATA2* gene codes for a transcription factor involved in gene regulation during the development and differentiation of hematopoietic cells, and its expression was shown to correlate with severe dysplasia in patients with primary MDS. Recently, heritable mutations in *GATA2* were identified in families with highly penetrant, early-onset MDS and/or AML. The mutations showed an autosomal-dominant pattern of inheritance, and affected individuals with this familial form of MDS/AML had poor outcomes in the absence of allogeneic HCT. More importantly, family members may not be eligible as donors for allogeneic HCT.

Determination of platelet-derived growth factor receptor beta (PDGFRβ) gene rearrangements is helpful for evaluating CMML/MPD patients with 5q31-33 translocations. The activation of this gene encoding a receptor tyrosine kinase for PDGFRβ has been identified in some of these patients. Data have shown that CMML/MPD patients with PDGFRβ fusion genes may respond well to treatment with the tyrosine kinase inhibitor imatinib mesylate.
Recurrent mutations in several genes can be found in MDS bone marrow and blood cells that may be clinically useful in specific contexts. For example, mutations in SF genes are much more common in patients with MDS, MDS-RS, and CMML compared to other myeloid neoplasms. Approximately 40% of MDS patients will carry a mutation in one of the three most frequently mutated SFs: SF3B1, SRSF2, and U2AF1. A typical mutation in one of these genes indicates the presence of clonally derived hematopoiesis and may help determine diagnosis in the appropriate clinical context.

Mutations of SF3B1 are associated with the presence of ring sideroblasts and are highly prevalent in patients with MDS-RS or MDS-RS-T (>80%).39 Mutations of JAK2 are found in 50% of MDS-RS-T, though it is much rarer in other subtypes. Mutations of SRSF2 are enriched in patients with CMML, although it is not unique to this subtype. Patients with JMML will often have mutations in one of the tyrosine kinase signaling genes such as PTPN11, NF1, NRAS, KRAS, or CBL. In many cases, these mutations are congenital and part of a larger syndrome.

Typical mutations in other genes (see Frequent Mutations in MDS-Associated Genes Likely to Indicate Clonal Hematopoiesis in the algorithm) can also establish the presence of clonal hematopoiesis, but they are less specific for disease subtype. Of note, several mutated genes associated with MDS (eg, TET2, DNMT3A, SF3B1, EZH2, NRAS, BRAF, TP53) can be mutated in other neoplasms, including lymphoid malignancies. Rare patients can have dual diagnoses (eg, MDS and chronic lymphocytic leukemia), which can confound the interpretation of sequencing results. Therefore, the presence of mutations must be interpreted in an appropriate clinical context consistent with MDS. Acquired mutations of TET2 and DNMT3A are frequent in MDS but have also been identified in older persons with clonal hematopoiesis and normal blood counts. Whether mutations of these or other genes are predictive of MDS in patients with cytopenias who do not meet morphologic diagnostic criteria for MDS is not known. Therefore, somatic mutations should not be used as presumptive evidence of MDS in the absence of other diagnostic features. Patients with cytopenias who lack bone marrow findings diagnostic of MDS can have somatic mutations indicative of clonal hematopoiesis, but the clinical outcomes for these patients are not known. The mere presence of a mutation is not a substitute for the pathologic diagnosis of MDS and should not be used as the sole indication for treatment. Mutations in some non-MDS genes may indicate the presence of neoplasms that can mimic MDS. These include CALR mutations associated with primary myelofibrosis, CSF3R mutations associated with aCML and chronic neutrophilic leukemia, and STAT3 mutations associated with LGL leukemia.

For discussion regarding the prognostic value of molecular abnormalities, see Molecular Abnormalities in MDS.

**Evaluation of Related Anemia**

Major morbidities of MDS include symptomatic anemia and associated fatigue. Progress has been made in the management of MDS-related anemia; however, the health care provider must also identify and treat any coexisting causes of anemia. Standard assessments should be performed to look for other causes of anemia, such as GI bleeding, hemolysis, renal disease, and nutritional deficiency. If needed, iron, folate, or vitamin B₁₂ studies should be obtained and the cause of depletion corrected, if possible. After excluding or providing proper treatment for these causes of anemia, further consideration for treating MDS-related anemia should be undertaken. Anemia related to MDS commonly presents as a hypoproductive macrocytic anemia, often
associated with suboptimal elevation of sEpo levels. Bone marrow aspiration with iron stain, biopsy, and cytogenetics should be used to determine WHO subtype, iron status, and the level of ring sideroblasts.

Prognostic Stratification

Although the diagnostic criteria allow for categorization of patients with MDS, the highly variable clinical outcomes within these subgroups indicate prognostic limitations. The morphologic features contributing to this variability include the wide range of marrow blast percentages for patients with MDS-EB (5%–19%) and CMML (1%–19%); marrow cytogenetics; and the degree and number of morbidity-associated cytopenias. These well-perceived problems for categorizing patients with MDS have led to the development of additional risk-based stratification systems.

Prognostic Scoring Systems

IPSS

The IPSS for primary MDS emerged from deliberations of the International MDS Risk Analysis Workshop (IMRAW). Compared with previous classification systems, the risk-based IPSS markedly improved prognostic stratification of MDS cases. The IPSS was developed based on the combined cytogenetic, morphologic, and clinical data from a relatively large group of MDS cases included in previously reported prognostic studies. FAB morphologic criteria were used to establish the diagnosis of MDS. In addition, relative stability of peripheral blood counts for 4 to 6 weeks was needed to exclude other possible etiologies for the cytopenias, such as drugs, other diseases, or incipient evolution to AML. CMML was subdivided into proliferative and non-proliferative subtypes. Patients with proliferative-type CMML (those with WBC counts >12,000/mcL) were excluded from this analysis. Patients with non-proliferative CMML (with WBC counts of ≤12,000/mcL plus other features of MDS) were included.

Significant independent variables for determining survival and AML evolution outcomes were marrow blast percentage, number of cytopenias, and cytogenetic subgroup (good, intermediate, and poor). Patients with the chromosome subgroup (8;21) or inv(16) were considered to have AML and not MDS, regardless of the blast count. Age was also a critical variable for survival, although not for AML evolution. The percentage of marrow blasts was divisible into four categories: 1) less than 5%; 2) 5% to 10%; 3) 11% to 20%; and 4) 21% to 30%.

Cytopenias were defined for the IPSS as a hemoglobin level less than 10 g/dL, an absolute neutrophil count below 1800 cells/mcL, and a platelet count below 100,000 cells/mcL. Patients with normal marrow karyotypes, del(5q) alone, del(20q) alone, and -Y alone had relatively good prognoses (70%), whereas patients with complex abnormalities (three or more chromosome abnormalities) or chromosome 7 anomalies had relatively poor prognoses (16%). The remaining patients were classified as having intermediate outcome (14%). Of the patients in the “complex” category, the vast majority had chromosome 5 or 7 abnormalities in addition to other anomalies.

To develop the IPSS for MDS, relative risk scores for each significant variable (marrow blast percentage, cytogenetic subgroup, and number of cytopenias) were generated. By combining the risk scores for the three major variables, patients were stratified into four distinctive risk groups in terms of both survival and AML evolution: low, intermediate (int)-1, int-2, and high. When either cytopenias or cytogenetic subtypes were omitted from the classification, discrimination among the four subgroups was much less precise. Both for survival and AML evolution,
the IPSS showed statistically greater prognostic discriminating power than earlier classification methods.\textsuperscript{14}

**WPSS**

Data have indicated a benefit to the addition of other clinical variables to the IPSS to improve the accuracy of prognosis. The WHO classification-based prognostic scoring system (WPSS) incorporates the WHO morphologic categories, the IPSS cytogenetic categories, and the degree of RBC transfusion dependence.\textsuperscript{144} This system demonstrated that the requirement for RBC transfusions is a negative prognostic factor for patients in the lower-risk MDS categories. In addition, depth of anemia \textit{per se} has additive and negative prognostic importance for the intermediate IPSS categories.\textsuperscript{145} As compared with the four groups defined by the IPSS, the WPSS classifies patients into five risk groups differing in both survival and risk of AML. The five risk groups are: very low, low, intermediate, high, and very high. Following the initial report by Malcovati et al.,\textsuperscript{144} there have been confirmatory studies demonstrating the usefulness of the WPSS.\textsuperscript{146-148} The initial WPSS has been refined to address the notion that the requirement for RBC transfusion may be somewhat subjective. In the refined WPSS, the measure of the degree of anemia by transfusion dependency is replaced by the presence (or absence) of severe anemia, defined as hemoglobin levels less than 9 g/dL for males and less than 8 g/dL for females.\textsuperscript{149} This approach allows for an objective assessment of anemia, while maintaining the prognostic implications of the five risk categories defined in the original WPSS (as mentioned above).\textsuperscript{149}

**IPSS-R**

The IPSS-R defines five risk groups (very low, low, intermediate, high, and very high) versus the four groups in the initial IPSS.\textsuperscript{150} The IPSS-R, which was derived from an analysis of a large dataset from multiple international institutions, refined the original IPSS by incorporating the following into the prognostic model: more detailed cytogenetic subgroups, separate subgroups within the “marrow blasts <5%” group, and a depth of cytopenias measurement defined with cut-offs for hemoglobin levels, platelet counts, and neutrophil counts. In the IPSS-R, the cytogenetic subgroups comprise five risk groups (vs. three in the original IPSS) based on a cytogenetic scoring system for MDS published in 2012.\textsuperscript{15} Other parameters including age, performance status, serum ferritin, LDH, and beta-2 microglobulin provided additional prognostic information for survival outcomes, but not for AML evolution; age was more prognostic among lower-risk groups compared with the higher-risk groups.\textsuperscript{150} The predictive value of the IPSS-R was validated in a number of independent studies based on registry data, including studies that evaluated outcomes for patients treated with hypomethylating agents.\textsuperscript{151-156}

In a multiregional study of MDS patient registry data from Italy (N = 646), significant differences in outcomes among the IPSS-R risk categories were found for OS, AML evolution, and progression-free survival (PFS) (later defined as leukemic evolution or death from any cause).\textsuperscript{157} Notably, the predictive power (based on Harrell’s C statistics) of the IPSS-R was found to be greater than the IPSS, WPSS, and refined WPSS for the three outcome measures mentioned above. The investigators acknowledged the limitation of a short follow-up (median, 17 months) in the study cohort.\textsuperscript{157}

In a retrospective analysis of data from lower-risk MDS (IPSS low or int-1) patients in a large multicenter registry (N = 2410) in Spain, the IPSS-R could identify 3 risk categories (very low, low, intermediate) within the IPSS low-risk group with none of the patients categorized as IPSS-R high or very high.\textsuperscript{158} Within the IPSS int-1-risk group, the IPSS-R further stratified patients into 4 risk categories (very low, low, intermediate, high) with only 1 patient categorized as very high risk. The IPSS-R was
significantly predictive of survival outcomes in both the subgroups of IPSS low and int-1 patients. Within the IPSS low-risk group, median survival based on the IPSS-R risk categories was 118.8 months for very low, 65.9 months for low, and 58.9 months for intermediate (P < .001). Within the IPSS int-1 risk group, median survival based on the IPSS-R risk categories was 113.7 months for very low, 60.3 months for low, 30.5 months for intermediate, and 21.2 months for high risk (P < .001). In addition, within the IPSS int-1 risk group (but not for the IPSS low-risk group), IPSS-R was significantly predictive of the 3-year rate of AML evolution. Thus, in this analysis, the IPSS-R appeared to provide prognostic refinement within the IPSS int-1 group, with a large proportion of patients (511 of 1096 IPSS int-1 patients) identified as having poorer prognosis (median survival, 21–30 months). This study also applied the refined WPSS to further stratify the IPSS low and int-1 risk groups, and was able to identify a group of patients (refined WPSS high-risk group) within the IPSS int-1 group who had poorer prognosis (185 of 1096 IPSS int-1 patients; median survival, 24.1 months). However, the IPSS-R identified a larger proportion of poor-risk IPSS int-1 patients than the refined WPSS (47% vs. 17%).

In a retrospective database analysis of MDS patients from a single institution (N = 1088), median OS according to IPSS-R risk categories was 90 months for very-low-, 54 months for low-, 34 months for intermediate-, 21 months for high-, and 13 months for very-high-risk groups (P < .005). The median follow-up in this study was 70 months. IPSS-R was also predictive of survival outcomes among the patients who received therapy with hypomethylating agents (n = 618). Compared to patients not receiving 5-azacitidine (AzaC), a significant survival benefit with AzaC was shown only for the groups of patients with very-high-risk (median survival, 18 vs. 25 months, respectively; P < .028) and high-risk IPSS-R (median survival, 15 vs. 9 months, respectively; P = .005). In addition, significantly longer OS with allogeneic HCT was only observed for patients at high (median survival, 40 vs. 19 months without HCT; P < .005) and very high (median survival, 31 vs. 12 months without HCT; P < .005) risk. The IPSS-R may therefore provide a tool for therapeutic decision-making.

A recent study applied the IPSS-R to a series of t-MDS and oligoblastic t-AML (ot-AML) patients. Although some IPSS-R cutpoints were suboptimal for t-MDS/ot-AML patients, the overall IPSS-R scores separated t-MDS/ot-AML patients into five risk groups, with each category showing statistical differences in OS as well as AML progression probability in t-MDS. These findings indicated that the major IPSS-R variables (bone marrow blast count, cytopenias, and cytogenetic data) remained powerful predictors in the therapy-related setting. However, compared to de novo MDS/oligoblastic AML, the median OS for each IPSS-R risk group of patients was shorter in t-MDS/ot-AML, particularly in the very-low- and low-risk groups. These differences likely reflect a number of factors, including different biology and clinical approaches (eg, treatment, primary disease, and its therapies) between t-MDS/ot-AML and de novo disease. Data from the MDS Clinical Research Consortium similarly demonstrated the improved prognostic value of the IPSS-R in 370 t-MDS patients compared to the IPSS, the global MD Anderson risk model, or the t-MDS MD Anderson model. Further studies are warranted to better evaluate the impact of specific therapies and more refined variables and their cutpoints for analysis of this heterogeneous group of patients.

Other recent studies have confirmed the value of the IPSS-R in treated as well as untreated patients. Since more accurate risk stratification by the IPSS-R compared to the IPSS and WPSS has been demonstrated, the IPSS-R categorization is preferred, although other systems have good value. It is understood that some
ongoing studies are using the IPSS or WPSS. Thus, a transition period is expected before more uniform prognostic risk stratification is accepted by the field. Recent analysis of patients in the International Working Group (IWG) for Prognosis in MDS database, which generated the IPSS-R, indicated that optimal prognostic separation of lower versus higher-risk patients was obtained by a dichotomization based on 3.5 scoring points of the IPSS-R raw score (ie, ≤3.5 vs. >3.5).164

LR-PSS
The Lower-Risk Prognostic Scoring System (LR-PSS), developed by investigators at the MD Anderson Cancer Center, is a prognostic model used in the evaluation of MDS, and was designed to help identify patients with lower-risk disease (IPSS low or int-1) who may have a poor prognosis.165 The prognostic model was developed using clinical and laboratory data from patients with IPSS low- (n = 250) and int-1– (n = 606) risk MDS. Factors associated with decreased survival were identified and a prognostic model was constructed based on the results of multivariate Cox regression analysis. The final model included the following factors that were independent predictors for survival outcomes: unfavorable cytogenetics, older age (≥60 years), decreased hemoglobin (<10 g/dL), decreased platelet count (<200 × 10^9/L), and higher percentage of bone marrow blasts (≥4%).165 Importantly, the cytogenetic categories in this system were derived from the previously defined IPSS categories rather than from the more refined IPSS-R. Each of these factors was given a weighted score, and the sum of the scores (range, 0–7 points) was used to generate 3 risk categories: a score of 0 to 2 points was assigned to category 1, a score of 3 or 4 was assigned to category 2, and a score of 5 to 7 was assigned to category 3. Using this scoring system, median survival was 80.3 months for category 1, 26.6 months for category 2, and 14.2 months for category 3; the 4-year survival rates were 65%, 33%, and 7%, respectively. The scoring system allowed for further stratification into these 3 risk categories for both the IPSS low-risk and IPSS int-1-risk subgroups.165 The LR-PSS may be useful in identifying patients with lower-risk disease who have poorer prognosis and require earlier treatment.

The prognostic value of the LR-PSS has been validated in several independent studies.40,158,166-168 In a retrospective analysis of data from lower-risk MDS (IPSS low or int-1) patients in the multicenter Spanish registry (N = 2410), the LR-PSS was able to further stratify these lower-risk patients into 3 risk categories.158 The LR-PSS was significantly predictive of survival outcomes in both the subgroups of IPSS low and int-1 patients. Within the IPSS low-risk group, median survival was 130.3 months for category 1 (low risk), 69.7 months for category 2 (intermediate risk), and 58.4 months for category 3 (high risk) using the LR-PSS–risk categories (P < .001); the corresponding median survival values within the IPSS int-1–risk group using the LR-PSS–risk categories were 115.2 months, 51.3 months, and 24.1 months, respectively (P < .001). An important proportion of patients (334 of 1096 patients; 30.5%) within the IPSS int-1–risk group were identified as having a poorer prognosis as indicated by their inclusion in the high-risk group (24.1 months). Within the IPSS int-1–risk group (but not for IPSS low risk), the LR-PSS was significantly predictive of the rate of AML evolution at 3 years.158

Data from a cohort of lower-risk MDS patients from two centers (N = 664) demonstrated a median survival according to the LR-PSS risk categories of 91.4 months for category 1, 35.6 months for category 2, and 22 months for category 3.168 Using data from the same cohort of patients, median survival according to the IPSS-R–risk groups was 91.4 months for IPSS-R very good, 35.9 months for good, and 27.8 months for the combined intermediate-, high-, and very-high-risk groups. Both of these prognostic scoring systems were significantly predictive of
survival outcomes. The predictive powers (based on Harrell’s C statistics) of the LR-PSS and IPSS-R were 0.64 and 0.63, respectively.\(^{168}\)

**Molecular Abnormalities in MDS**

In recent years, several gene mutations have been identified among patients with MDS that may, in part, contribute to the clinical heterogeneity of the disease course, and thereby influence the prognosis of patients. Such gene mutations will be present in the majority of newly diagnosed patients, including most patients with normal cytogenetics. Several studies examining large numbers of MDS tumor samples have identified more than 40 recurrently mutated genes with greater than 80% of patients harboring at least one mutation.\(^{40,169-171}\) The most frequently mutated genes were \textit{TET2}, \textit{SF3B1}, \textit{ASXL1}, \textit{DNMT3A}, \textit{SRSF2}, \textit{RUNX1}, \textit{TP53}, \textit{U2AF1}, \textit{EZH2}, \textit{ZRSR2}, \textit{STAG2}, \textit{CBL}, \textit{NRAS}, \textit{JAK2}, \textit{SETBP1}, \textit{IDH1}, \textit{IDH2}, and \textit{ETV6}, although no single mutated gene was found in more than a third of patients. Several of these gene mutations are associated with adverse clinical features such as complex karyotypes (\textit{TP53}), excess bone marrow blast proportion (\textit{RUNX1}, \textit{NRAS}, and \textit{TP53}), and severe thrombocytopenia (\textit{RUNX1}, \textit{NRAS}, and \textit{TP53}).

Despite associations with clinical features considered by prognostic scoring systems, mutations in several genes hold independent prognostic value. Mutations of \textit{TP53}, \textit{EZH2}, \textit{ETV6}, \textit{RUNX1}, and \textit{ASXL1} have been shown to predict decreased OS in multivariable models adjusted for IPSS or IPSS-R risk groups in several studies of distinct cohorts.\(^{169,171}\) Within IPSS risk groups, a mutation in one or more of these genes identifies patients whose survival risk resembles that of patients in the next highest IPSS risk group (eg, the survival curve for int-1–risk patients with an adverse gene mutation was similar to that of patients assigned to the int-2–risk group by the IPSS).\(^{169}\) When applied to patients stratified by the IPSS-R, the presence of a mutation in one or more of these five genes was associated with shorter OS for patients in the low- and intermediate-risk groups.\(^{171}\) Thus, the combined analysis of these gene mutations and the IPSS or IPSS-R may improve upon the risk stratification provided by these prognostic models alone. Mutations of \textit{ASXL1} have also been shown to carry independent adverse prognostic significance in CMML.\(^{172,173}\) Other mutated genes have been associated with decreased OS, including \textit{DNMT3A}, \textit{U2AF1}, \textit{SRSF2}, \textit{CBL}, \textit{PRPF8}, \textit{SETBP1}, and \textit{KRAS}.\(^{169,171,174-177}\) Only mutations of \textit{SF3B1} have been associated with a more favorable prognosis even after adjustment for the IPSS-R in several, but not all studies.\(^{171,178,179}\)

\textit{TET2} mutations have been shown to impact the response to hypomethylating agents.\(^{180,181}\) Patients with mutated \textit{TET2} had an 82% response rate to AzaC compared to 45% of patients with wildtype \textit{TET2} (\textit{P} = .007). Response duration and OS were not statistically different.\(^{180}\) Another study identified 39 genes that were mutated in 213 patients with MDS treated with AzaC or decitabine.\(^{181}\) A higher response to hypomethylating agents in patients with the \textit{TET2} mutation, albeit to a lesser degree, was seen (response rate, 55% vs. 44%; \textit{P} = .14). This improved response was more pronounced when patients with \textit{ASXL1} mutations and those with only low abundance \textit{TET2} mutations were excluded (OR, 3.65; \textit{P} = .009). Mutations in \textit{TP53} and \textit{PTPN11} correlated with shorter OS but did not affect drug response. However, the predictive capabilities of these mutations are modest. The status of these molecular markers in patients should not preclude the use of hypomethylating agents nor be used to influence the selection of hypomethylating agents.

Mutations of \textit{TP53} are strongly associated with complex and monosomal karyotypes. However, approximately 50% of patients with a
complex karyotype have no detectable \textit{TP53} abnormality and have an OS that is comparable to that of patients with non-complex karyotypes. Therefore, \textit{TP53} mutation status may be useful for refining the prognosis of these patients typically considered to have higher-risk disease.\textsuperscript{169} Patients with del(5q), either as an isolated abnormality or often as part of a complex karyotype, have a higher rate of concomitant \textit{TP53} mutations.\textsuperscript{182,183} These mutations are associated with diminished response or relapse after treatment with lenalidomide.\textsuperscript{184,185} In these cases, \textit{TP53} mutations may be secondary events and are often present in small subclones that can expand during treatment. More sensitive techniques may be required to identify the presence of subclonal, low-abundance \textit{TP53} mutations prior to treatment.

Mutations identified in peripheral blood samples can accurately reflect mutations detected in the bone marrow of patients with MDS when more sensitive sequencing techniques are used to detect them.\textsuperscript{186}

\textbf{Comorbidity Indices}

Patients with MDS predominantly comprise an elderly adult population, posing potential challenges in terms of treatment tolerability and outcomes due to the presence of comorbid conditions. About 50\% of patients with newly diagnosed MDS present with one or more comorbidities, with cardiac disease and diabetes among the most frequently observed conditions.\textsuperscript{187-191} Assessment of the presence and degree of comorbidities using tools such as the Charlson Comorbidity Index (CCI) or the Hematopoietic Stem Cell Transplantation-Specific Comorbidity Index (HCT-CI) has demonstrated the significant prognostic influence of comorbidities on the survival outcome of patients with MDS.\textsuperscript{187,189-191} Recent studies have shown that comorbidity (as measured by HCT-CI or Adult Comorbidity Evaluation-27) was a significant prognostic factor for survival, independent of IPSS.\textsuperscript{188,191} In these studies, comorbidity indices provided additional prognostic information for survival outcomes in patients categorized as IPSS intermediate or high risk, but not for patients considered to have low-risk disease.

Conversely, in another study, comorbidity (as measured by HCT-CI or CCI) was a significant predictor of OS and event-free survival in patients within the low-risk or int-1–risk groups, but not in the int-2–risk or high-risk groups.\textsuperscript{189} Comorbidity has also been shown to provide additional risk stratification among WPSS risk categories (for very low-, low-, and intermediate-risk groups but not for high- or very-high-risk groups), prompting the development of a new MDS-specific comorbidities index that can be used in conjunction with WPSS for the assessment of prognosis.\textsuperscript{192} Improved risk stratification has also been demonstrated with the incorporation of the Myelodysplastic Syndromes Comorbidity Index with the IPSS-R.\textsuperscript{163} At this time, the NCCN MDS Panel makes no specific recommendations with regard to the optimal comorbidity index to be used for patients with MDS. However, a thorough evaluation of the presence and extent of comorbid conditions remains an important aspect of treatment decision-making and management of patients with MDS.

\textbf{Therapeutic Options}

The IPSS or IPSS-R risk categories are used in the initial planning of therapeutic options, because they provide a risk-based patient evaluation (category 2A). In addition, factors such as patient age, performance status, and presence of comorbidities are critical determinants, because they have a major influence on the patient’s ability to tolerate certain intensive treatments. The WPSS provides dynamic estimation of prognosis at any time during the course of MDS.
If the patient was only recently evaluated, determining the relative stability of the patient’s blood counts over several months is important to assess whether the disease progresses, including incipient transformation to AML. In addition, this assessment permits determination of other possible etiologies for cytopenias. The patient’s preference for a specific approach is also important in deciding treatment options. The therapeutic options for MDS include supportive care, low-intensity therapy, high-intensity therapy including allogeneic HCT, and participation in a clinical trial. In evaluating results of therapeutic trials, the panel found it important for studies to use the standardized IWG response criteria.\(^{193-195}\)

For the MDS therapeutic algorithm, all patients should receive relevant supportive care. Following that, the MDS Panel has proposed initially stratifying patients with clinically significant cytopenia(s) into two major risk groups: 1) lower-risk patients (ie, IPSS low, int-1; IPSS-R very low, low, intermediate; WPSS very low, low, intermediate); and 2) higher-risk patients (ie, IPSS int-2, high; IPSS-R intermediate, high, very high; WPSS high, very high). Patients who fall under the IPSS-R intermediate category may be managed as either of the two risk groups depending on evaluation of additional prognostic factors such as age, performance status, serum ferritin levels, and serum LDH levels.\(^{150}\) In addition, intermediate-risk patients with disease that does not respond to therapy for lower-risk disease would be eligible to receive therapy for higher-risk MDS.

Based on IWG response criteria, the major therapeutic aim for patients in the lower-risk group would be hematologic improvement, whereas for those in the higher-risk group, alteration of the natural history of disease is viewed as paramount. Cytogenetic response and quality-of-life (QOL) parameters are also important outcomes to assess. The algorithm outlines management of primary MDS only. Most patients with t-MDS have poorer prognoses than those with primary MDS, including a substantial proportion with poor-risk cytogenetics. These patients are generally managed as having higher-risk disease.

**Supportive Care**

Currently, the standard of care for MDS management includes supportive care measures (see Supportive Care in the algorithm and the NCCN Guidelines for Supportive Care). This entails observation, clinical monitoring, psychosocial support, and QOL assessment. Major efforts should be directed toward addressing the relevant QOL domains (eg, physical, functional, emotional, spiritual, social), which adversely affect the patient. Supportive care should include RBC transfusions for symptomatic anemia as needed (generally leukocyte-reduced) or platelet transfusions for bleeding events; however, platelet transfusions should not be used routinely in patients with thrombocytopenia in the absence of bleeding. Both the number of transfusions as well as the number of packed RBCs per transfusion should be kept to a minimum in non-cardiac patients and in patients anticipated to be heavily transfused. The NCCN Guidelines Panel is in agreement with the 2013 American Society of Hematology (ASH) Choosing Wisely\(^{®}\) initiative addressing hematologic tests and treatments.\(^{196}\) There was non-uniform consensus among the panel members based on differing institutional policies regarding the necessity for routine irradiation of blood products used in patients with MDS; however, the panel agreed that all directed-donor products and transfused products for potential HCT patients should be irradiated. Additionally, CMV-negative blood products are recommended whenever possible for CMV-negative recipients. In the absence of CMV-negative blood, leuko-reduced blood may be used. Aminocaproic acid or other antifibrinolytic agents may be considered for bleeding episodes refractory to platelet transfusions or for profound thrombocytopenia. Hematopoietic cytokine support should...
be considered for refractory symptomatic cytopenias. For example, recombinant human granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage CSF (GM-CSF) treatment could be considered for neutropenic MDS patients with recurrent or resistant bacterial infections.

**Management of Thrombocytopenia**

Severe thrombocytopenia is associated with an increased risk for bleeding events, and is currently managed with platelet transfusions. The mechanism of thrombocytopenia in patients with MDS may be attributed to decreased platelet production (possibly related to regulatory pathways involving the production and/or metabolism of endogenous thrombopoietin [TPO]) as well as increased destruction of bone marrow megakaryocytes or circulating platelets. Increased endogenous TPO levels have been reported among patients with MDS compared with healthy individuals. At the same time, TPO receptor sites per platelet were decreased among patients with MDS compared with healthy subjects. The RA subgroup (as defined by Bennett et al) appeared to have the highest TPO levels compared with MDS-EB or MDS-EB-T patients, while the number of TPO receptor sites remained similar across subtypes. Studies have reported that high endogenous TPO levels correlated with decreased platelet counts in RA patients, but not in MDS-EB or MDS-EB-T patients. This observation suggests that the regulatory pathway for endogenous TPO may be further disrupted in the latter group, potentially due to overexpression of TPO receptors in blasts that could lead to an inadequate TPO response.

Several studies are investigating the role of the TPO receptor agonist romiplostim in the treatment of thrombocytopenia in patients with lower-risk MDS. Phase I/II studies with romiplostim showed promising rates of platelet response (46%–65%) in patients with lower-risk MDS. Randomized placebo-controlled studies in patients treated for lower-risk MDS have reported beneficial effects of romiplostim in terms of decreased bleeding events, reduced need for platelet transfusions in patients receiving hypomethylating agents and decreased frequency of dose reductions or delays in patients receiving lenalidomide therapy. In a randomized study including patients with low or int-1 risk MDS (n = 250), romiplostim was associated with increased platelet counts and decreased overall bleeding events ($P = .026$ after 58 weeks of treatment compared to the placebo group). However, due to the early drug discontinuation, interpretation of these data is limited. Following up on previous studies, an open-label extension study evaluated the long-term safety and efficacy of romiplostim in 60 patients with lower-risk MDS and found that most patients achieved durable responses. A model to predict response to romiplostim indicated that lower-risk MDS, lower baseline TPO levels (<500 pg/mL), and limited platelet transfusion history had the greatest effect on subsequent platelet response to romiplostim.

Eltrombopag is another TPO receptor agonist that has been shown to increase normal megakaryopoiesis in vitro in bone marrow cells isolated from patients with MDS. Ongoing phase I and II clinical trials are investigating the activity and safety of this agent for the treatment of thrombocytopenia in patients with lower-risk MDS. Early data from a phase II, multicenter, prospective, placebo-controlled study indicate that eltomboag may significantly improve platelet counts and fatigue. This study enrolled 70 patients with low-risk or IPSS intermediate-1 risk MDS and severe thrombocytopenia who were randomized 2:1 to receive eltomboag or placebo. At the time of interim analysis, 23 patients (50%) receiving eltomboag had an improvement in platelet counts compared with 2 patients (8%) in the placebo control group ($P = .016$), while there were no significant changes in the placebo
A recent follow-up report with additional patients (n = 90) demonstrated improved platelet responses in patients in the eltrombopag group when compared to the placebo group (47% vs. 3%, respectively; \( P = .0017 \)).

A phase II trial is evaluating eltrombopag in combination with hypomethylating agents in adults who have had greater than 4 cycles of hypomethylating agents but who have disease that fails to respond to treatment or disease that continues to have ongoing cytopenias. Out of 23 patients enrolled in the study, 16 had an evaluable response. Although platelet improvement was seen in 3 patients and 8 patients remain on study with stable disease, these results are very preliminary and a larger prospective trial is needed. Another phase II trial is evaluating eltrombopag for thrombocytopenia in adult patients with intermediate-2 or high-risk MDS and AML.

Concerns for potential proliferation of leukemic blasts in response to exogenous TPO have been raised in earlier in vitro studies, particularly for high-risk MDS cases. Results from ongoing clinical trials with the TPO mimetics will help to elucidate the risks for leukemic transformations in patients with MDS. It should be noted that neither romiplostim nor eltrombopag are currently approved for use in patients with MDS.

Management of Iron Overload

RBC transfusions are a key component in the supportive care of MDS patients. Although the specific therapies patients receive may alleviate RBC transfusion need, a substantial proportion of MDS patients may not respond to these treatments and may develop iron overload and its consequences. Thus, effective treatment of transfusional siderosis in MDS patients may be necessary.

Studies in patients requiring relatively large numbers of RBC transfusions (eg, thalassemia, MDS) have demonstrated the pathophysiology and adverse effects of chronic iron overload on hepatic, cardiac, and endocrine function. Increased non-transferrin-bound iron, generated when plasma iron exceeds transferrin-binding capacity, combines with oxygen to form hydroxyl and oxygen radicals. These toxic elements cause lipid peroxidation and cell membrane, protein, DNA, and organ damage.

Although limited, there is evidence suggesting that organ dysfunction can result from iron overload in patients with MDS. Retrospective data indicate that transfusional iron overload might be a contributor of increased mortality and morbidity in early-stage MDS. The WPSS has shown that the requirement for RBC transfusion is a negative prognostic factor for patients with MDS. In a meta-analysis including 8 observational studies, patients receiving iron chelation therapy had a longer median survival time compared to patients who did not receive therapy. The mean difference in median OS was 61.2 months, further supporting the need to control transfusional iron overload. However, prospective studies are required to substantiate the value of iron chelation in these patients.

For patients with chronic RBC transfusion need, serum ferritin levels and associated organ dysfunction (heart, liver, and pancreas) should be monitored. The NCCN Panel Members recommend monitoring serum ferritin levels and number of RBC transfusions received as a practical means to determine iron stores and assess iron overload. Monitoring serum ferritin may be useful, aiming to decrease ferritin levels to less than 1000 mcg/L. It is recognized that such measurements, though useful, are less precise than SQUID (Superconducting Quantum Interference Device), or more recently T2* MRI, to provide a specific measurement of hepatic iron content.
Reversal of some of the consequences of iron overload in MDS and other iron overload states by iron chelation therapy has been shown in patients in whom the most effective chelation occurred. This included transfusion independence (TI) in a subset of the small group of MDS patients who had undergone effective deferoxamine chelation for 1 to 4 years. In addition, improvement in cardiac iron content was demonstrated in these patients after chelation. Such findings have major implications for altering the morbidity of MDS patients, particularly those with pre-existing cardiac or hepatic dysfunction.

The availability of iron chelators, such as deferoxamine and deferasirox, provide potentially useful drugs to more readily treat iron overload. Deferoxamine (given as intramuscular or subcutaneous [SC] injections) is indicated for the treatment of chronic iron overload due to transfusion-dependent (TD) anemias. Deferasirox (given orally) is indicated for the treatment of chronic iron overload due to blood transfusions. Deferasirox has been evaluated in multiple phase II clinical trials in patients with TD-MDS. A large, multicenter, phase III, randomized controlled trial is currently underway to evaluate outcomes of deferasirox compared with placebo in patients with MDS; the primary endpoint of this ongoing study is event-free survival (registered at clinicaltrials.gov; NCT00940602). The prescribing information for deferasirox contains a black-box warning pertaining to the increased risks for renal or hepatic impairment/failure and GI bleeding in certain patient populations, including patients with high-risk MDS. Deferasirox is contraindicated in patients with high-risk MDS.

A third oral chelating agent, deferiprone, was approved (October 2011) in the United States for the treatment of patients with transfusional iron overload due to thalassemia when current chelation therapy is inadequate. FDA approval was based on results from a retrospective analysis of data pooled from previous safety and efficacy studies of deferiprone in patients with transfusion-related iron overload refractory to existing chelation therapy. The prescribing information for deferiprone contains a black-box warning pertaining to risks for agranulocytosis, which can lead to serious infections and death. Controversy remains regarding the use of this agent.

There are ongoing clinical trials in patients with MDS receiving oral iron-chelating agents to address whether iron chelation alters the natural history of patients who are TD. The NCCN Task Force report, titled Transfusion and Iron Overload in Patients with Myelodysplastic Syndromes, provides detailed evidence regarding iron chelation in patients with MDS.

The NCCN Guidelines Panel recommends consideration of once-daily deferoxamine SC or deferasirox/ICL670 orally to decrease iron overload (aiming for a target ferritin level less than 1000 ng/mL) in the following IPSS low- or int-1–risk patients: 1) patients who have received or are anticipated to receive greater than 20 RBC transfusions; 2) patients for whom ongoing RBC transfusions are anticipated; and 3) patients with serum ferritin levels greater than 2500 ng/mL.

As mentioned above, a black-box warning was added to the prescribing information for deferasirox. Following post-marketing use of deferasirox, there were case reports of acute renal failure, or hepatic failure, some of which were fatal. Most of the fatalities reported were in patients with multiple comorbidities and in advanced stages of their hematologic disorders. Additionally, there were post-marketing reports of cytopenias, including agranulocytosis, neutropenia, and thrombocytopenia, and GI bleeding in patients treated with deferasirox; some cases resulted in death. The relationship of these episodes to treatment with deferasirox has not yet been established. However, it is recommended that patients on deferasirox therapy be closely monitored.
monitored. Monitoring should include measurement of serum creatinine and/or creatinine clearance and liver function tests prior to initiation of therapy and regularly thereafter. Deferasirox and deferoxamine should be avoided in patients with creatinine clearance less than 40 mL/min.231

Treatment of Related Anemia

Erythropoiesis-stimulating agents (ESAs) such as recombinant human Epo (rHu Epo) or the longer-acting darbepoetin, with or without G-CSF, have been evaluated in the treatment of symptomatic anemia in patients with MDS. Studies predominantly in lower-risk MDS patients have demonstrated erythroid response rates of 40% and 60% (combined major and minor responses using IWG response criteria) in the initial trials.239,240 Clinical trial results in patients with MDS have suggested that the overall response rates to darbepoetin are similar to or possibly higher than epoetin.239-242 The improved response rates may in part be due to the dosage used (150–300 mcg SC per week) or to the fact that better-risk patients were enrolled in studies of darbepoetin compared to epoetin. Features predictive of response have included relatively low basal sEpo levels, low percentage of marrow blasts, and few prior RBC transfusions.

In a phase II study in patients with MDS (RA, MDS-RS, and MDS-EB; N = 50), Epo combined with G-CSF (n = 47 evaluable) resulted in hematologic responses in 38% of patients (complete response [CR], 21%).243 Epo and G-CSF appeared to have synergistic activity. Lower sEpo levels (<500 μU/mL) and a lower pretreatment RBC transfusion requirement (<2 units per month) were associated with a higher response rate; response rates were not significantly different across IPSS risk groups.243 Median survival, including patients from a prior study, was 26 months (N = 71). Among patients with low-risk IPSS, median survival had not been reached at 5 years; the 5-year survival rate was 68%. Median survival times among the int-1– and int-2–risk groups were 27 months and 14 months, respectively. AML progression occurred in 28% of patients overall during the observation period. The frequency of AML progression in the low-, int-1–, int-2–, and high-risk groups were 12%, 21%, 45%, and 100%, respectively. Among patients with responding disease who received maintenance treatment with Epo and G-CSF, the median duration of response was 24 months.243

A subsequent analysis of combined data from three phase II Nordic trials (n = 121) on the long-term outcomes with Epo plus G-CSF (given for 12–18 weeks and followed by maintenance in responders) in patients with MDS reported a hematologic response rate of 39% with a median duration of response of 23 months.244 Long-term outcomes were compared with outcomes from untreated patients (n = 237) as controls. Based on multivariate Cox regression analysis, treatment with Epo plus G-CSF was associated with a significantly improved survival outcome (hazard ratio [HR], 0.61; 95% CI, 0.44–0.83; P = .002). An exploratory analysis revealed that the association between treatment and survival was significant only for the IPSS low-risk group and was further restricted to patients requiring fewer than 2 units of RBC transfusions per month. No significant association was found between the treatment and frequency of AML progression.244

Similar findings were reported in a study from the French myelodysplasia group, which analyzed outcomes with ESAs (epoetin or darbepoetin), with or without G-CSF, in MDS patients with anemia (N = 403).245 Based on the IWG 2000 criteria, the hematologic response rate was 62% with a median duration of 20 months; the corresponding results from the IWG 2006 criteria were 50% and 24 months, respectively. IPSS low- or int-1-risk was associated with significantly higher response rates and longer response durations. In a comparison of outcomes (in the low- or int-1-risk subset with anemia) between
treated patients (n = 284) and a historical cohort of untreated patients (n = 225), multivariate analysis showed a significant association between treatment with ESAs and survival outcomes. The frequency of AML progression was similar between the cohorts. In a phase II study that evaluated darbepoetin (given every 2 weeks for 12 weeks), with or without G-CSF (added at 12 weeks in non-responders), patients in the lower-risk IPSS group with anemia (and sEpo levels <500 mU/mL) had hematologic response rates of 48% at 12 weeks and 56% at 24 weeks. Median duration of response was not reached at the median follow-up of 52 months. The 3-year cumulative incidence of AML progression was 14.5%, and the 3-year survival rate was 70%. This study also showed improvements in QOL parameters among patients with responding disease.

Collectively, these studies suggest that ESAs may provide clinical benefit to patients in the lower-risk group with symptomatic anemia. Limited data are available on the effectiveness of ESAs in the treatment of anemia in lower-risk patients with del(5q). Epo has been shown to promote the growth of cytogenetically normal cells isolated from patients with del(5q), while having minimal proliferative effects on MDS progenitor cells from these patients in vitro. Retrospective studies from the French group reported hematologic response rates between 46% and 64%, with a median response duration of 11 months (mean duration, 13–14 months) among patients with del(5q) treated with ESAs, with or without G-CSF. Duration of response in these patients was significantly decreased compared with patients without del(5q) (mean duration, 25–27 months). Based on multivariate analysis, del(5q) was a significant predictor of a shorter response duration with treatment (see Prognostic Category Low, Intermediate-1 Treatment in the algorithm).

In March 2007 and 2008, the FDA announced alerts and strengthened safety warnings for the use of ESAs based on observed increased mortality and possible tumor promotion and thromboembolic events in non-MDS patients receiving ESAs when dosing to achieve a targeted hemoglobin level greater than 12 g/dL. Specifically, the study patients had chronic kidney failure; were receiving radiation therapy for various malignancies, including head and neck cancer, advanced breast cancer, lymphoid cancer, or non-small cell lung cancer; were patients with cancer not receiving chemotherapy; or were orthopedic surgery patients. However, ESAs have been used safely in large numbers of adult MDS patients and have become important for symptomatic improvement of anemia caused by this disease, often with a decrease in RBC transfusion requirements. Studies assessing the long-term use of Epo with or without G-CSF in MDS patients have shown no negative impact of such treatment on survival or AML evolution when compared to either randomized controls or historical controls.

Jadersten et al reported improved survival in low-risk MDS patients with low transfusion need following treatment with these agents. In another study, improved survival and decreased AML progression of IPSS low or int-1 patients following Epo treatment, with or without G-CSF, compared to the historical control IMRAW database patients were reported. Thus, these data do not indicate a negative impact of these drugs in the treatment of MDS. Given these data, the NCCN Panel recommends the use of ESAs in the management of symptomatic anemia in MDS patients, with a target hemoglobin range of 10 to 12 g/dL but not exceeding 12 g/dL. Clinical trials with other experimental agents that are reportedly capable of increasing hemoglobin levels should be explored in patients with disease that is not responding to standard therapy. These drugs should be used in the context of therapeutic approaches for the underlying prognostic risk group.

In March 2007, the Centers for Medicare & Medicaid Services (CMS) generated a National Coverage Determination (NCD) on the use of
ESAs in non-renal disease applications. Following a public comment period, it was determined that the scope of the NCD should be revised to include cancer and related neoplastic conditions. The narrowed scope of the NCD excludes MDS as it is defined in the report as a premalignant condition and not an oncologic disease. Thus, local Medicare contractors may continue to make reasonable and necessary determinations on the use of ESAs that are not determined by the NCD.

Low-Intensity Therapy
Low-intensity therapy includes the use of low-intensity chemotherapy or biologic response modifiers. Although this type of treatment is mainly provided in the outpatient setting, supportive care or occasional hospitalization (eg, for treatment of infections) may be needed.

Hypomethylating Agents
The DNA methyltransferase inhibitor (DMTI) hypomethylating agents AzaC and decitabine (5-aza-2'-deoxycytidine) have been shown in randomized phase III trials to decrease the risk of leukemic transformation and, in a portion of patients, to improve survival. In a phase III trial that compared AzaC with supportive care in patients from all IPSS risk groups (N = 191; previously untreated in 83%), hematologic responses occurred in 60% of patients in the AzaC arm (7% CR, 16% partial response [PR], and 37% hematologic improvement) compared with a 5% hematologic improvement (and no responses) in patients receiving supportive care. The median time to AML progression or death was significantly prolonged in the AzaC arm compared with patients receiving supportive care (21 vs. 13 months; \( P = .007 \)). Further improvement was seen in patients who received AzaC earlier in the course of disease, suggesting that the drug prolonged the duration of stable disease. Subsequently, Silverman and colleagues provided a summary of three AzaC studies in a total of 306 patients with high-risk MDS. In this analysis, which included patients receiving either SC or intravenous (IV) delivery of the drug, complete remissions were seen in 10% to 17% of AzaC-treated patients and partial remissions were rare; hematologic improvement was seen in 23% to 36% of these patients. Ninety percent of the responses occurred prior to cycle 6 with a median number of cycles to first response of 3. The authors concluded that AzaC provided important clinical benefits for patients with high-risk MDS. Results from a phase III randomized trial in patients (N = 358) with higher-risk MDS (IPSS int-1, 5%; int-2, 41%; high risk, 47%) demonstrated that AzaC was superior to conventional care (ie, standard chemotherapy or supportive care) regarding OS. AzaC was associated with a significantly longer median survival compared with conventional care (24.5 vs. 15 months; HR, 0.58; 95% CI, 0.43–0.77; \( P = .0001 \)), thus providing support for the use of this agent in patients with higher-risk disease.

AzaC therapy should be considered for treating MDS patients with progressing or relatively high-risk disease. This drug has been approved by the FDA for the treatment of patients with MDS and is generally administered at a dose of 75 mg/m²/d SC for 7 days every 28 days for at least 6 courses. Treatment courses may need to be extended further or may be used as a bridging therapy to more definitive therapy (eg, patients whose marrow blast counts require lowering prior to HCT). Although the optimal duration of therapy with AzaC has not been defined, some data suggest that continuation of AzaC beyond first response may improve remission quality. In a secondary analysis of the phase III randomized AZA-001 trial, continued AzaC therapy resulted in further improvement in response category in 48% of all responders. Although most patients with responding disease achieved a first response by 6 cycles of therapy, up to 12 cycles were required for the majority of responders to attain a best response. In this study, the median number of cycles from first
response to best response was 3 to 3.5 cycles, and patients with responding disease received a median of 8 additional cycles (range, 0–27 cycles) beyond first response.  

An alternative 5-day schedule of AzaC has been evaluated, both as an SC regimen (including the 5-2-2 schedule: 75 mg/m\(^2\)/d SC for 5 days followed by 2 days of no treatment, then 75 mg/m\(^2\)/d for 2 days, every 28 days; and the 5-day schedule: 75 mg/m\(^2\)/d SC for 5 days every 28 days) and as an IV regimen (75 mg/m\(^2\)/d IV for 5 days every 28 days). Although response rates with the 5-day regimens appeared similar to the approved 7-day dosing schedule, survival benefit with AzaC has only been demonstrated using the 7-day schedule.  

Decitabine, given IV and administered with a regimen that required hospitalization of patients, has also shown encouraging results for the therapy of patients with higher-risk MDS. As the treatment regimen was generally associated with low-intensity–type toxicities, it is also considered to be a “low-intensity therapy.” In earlier phase II studies, approximately 30% of patients experienced cytogenetic conversion, with an overall response rate of 49%, and a 64% response rate in patients with a high-risk IPSS score; results were similar to those seen in AzaC studies.  

A phase III randomized trial of decitabine (15 mg/m\(^2\) IV infusion over 3 hours every 8 hours [ie, 45 mg/m\(^2\)/d] on 3 consecutive days every 6 weeks for up to 10 cycles) compared with supportive care in adult patients (N = 170) with primary and secondary MDS (IPSS int-1, 30.5%; int-2, 43.5%; high risk, 26%) indicated higher response rates, remission durations, times to AML progression, and survival benefits in the int-2 and high-risk groups. Overall response rate (CR + PR) with decitabine was 17% (median duration, 10 months), with an additional 13% of patients showing hematologic improvement. The probability of progression to AML or death was 1.68-fold greater for supportive care patients than for patients receiving decitabine. Based on this study and three supportive phase II trials, the drug has also been approved by the FDA for treating MDS patients.  

In another phase III randomized trial with this regimen, decitabine was compared with best supportive care (BSC) in patients age 60 years or older (N = 233; median age, 70 years; range, 60–90 years) with higher-risk MDS (IPSS int-1, 7%; int-2, 55%; high risk, 38%) not eligible for intensive therapy. Median PFS was significantly improved in patients receiving decitabine compared with supportive care (6.6 vs. 3 months; HR, 0.68; 95% CI, 0.52–0.88; P = .004), and the risk of AML progression at 1 year was reduced with decitabine (22% vs. 33%; P = .036). However, no significant differences were observed between decitabine and supportive care for the primary endpoint of OS (10 vs. 8.5 months, respectively) or for median AML-free survival (8.8 vs. 6.1 months, respectively). In the decitabine arm, a CR and PR were observed in 13% and 6% of patients, respectively, with hematologic improvement in an additional 15%; in the supportive care arm, hematologic improvement was seen in 2% of patients (with no hematologic responses). Decitabine was associated with significant improvements in patient-reported QOL measures (as assessed by the EORTC QOL Questionnaire C30) for the dimensions of fatigue and physical functioning.  

In 2007, Kantarjian and colleagues provided an update to their study of 115 patients with higher-risk MDS using alternative and lower-dose decitabine treatment regimens. Patients received 1 of 3 different schedules of decitabine, including both SC and IV administration with a mean of 7 courses of therapy. Responses were improved with the longer duration of therapy. Overall, 80 patients (70%) responded with 40 patients achieving a CR and 40 achieving a PR. The median
remission duration was 20 months with a median survival time of 22 months. The three different schedules of decitabine were compared in another randomized study of 95 patients with MDS or CMML, receiving 20 mg/m²/d IV for 5 days; 20 mg/m²/d SC for 5 days; or 10 mg/m²/d IV for 10 days. The 5-day IV schedule was considered the optimal schedule. The CR rate in this arm was 39%, compared with 21% in the 5-day SC arm and 24% in the 10-day IV arm (P < .05). Alternate dosing regimens using lower doses of decitabine administered in an outpatient setting are currently being evaluated.

Several retrospective studies have evaluated the role of cytoreductive therapy with hypomethylating agents prior to allogeneic HCT (with both myeloablative and reduced-intensity conditioning [RIC] regimens). These studies suggest that hypomethylating agents may provide a feasible alternative to induction chemotherapy regimens prior to transplant, and may serve as a bridge to allogeneic HCT. A randomized trial comparing the two strategies is currently ongoing (clinicaltrials.gov NCT01812252).

AzaC and decitabine are considered to be therapeutically similar, although the improved survival of higher-risk patients treated with AzaC compared to control patients in a phase III trial, as indicated above, supports the preferred use of AzaC in this setting until more trial data are available. A lack of CR, PR or hematologic improvement, or frank progression to AML (in particular with loss of control [proliferation] of peripheral counts or excess toxicity that precludes continuation of therapy) may be indicative of disease that fails to respond to hypomethylating agents. The minimum number of courses prior to considering the treatment a failure should be 4 courses for decitabine or 6 courses for AzaC. As discussed earlier, the optimal duration of therapy with hypomethylating agents has not been well-defined and no consensus exists. The NCCN Guidelines Panel generally feels that treatment should be continued if there is ongoing response and if there are no toxicities. Modifications should be made to the dosing frequency for individual patients in the event of toxicity.

As data have predominantly indicated altered natural history and decreased evolution to AML in patients who respond to DMTI hypomethylating agents, the major candidates for these drugs are 1) patients with IPSS int-2– or high-risk disease; or 2) IPSS-R intermediate-, high-, or very-high-risk disease with any of the following criteria:

- Patients who are not candidates for high-intensity therapy;
- Patients who are potential candidates for allogeneic HCT but for whom delay in receipt of that procedure is anticipated (eg, due to need to further reduce the blast count, improve patient performance status, identify a donor). In these circumstances, the drugs may be used as a bridging therapy for that procedure; or
- Patients who are not expected to respond to (or who relapsed after) ESAs or IST.

**Biologic Response Modifiers and Immunosuppressive Therapy**

The currently available non-chemotherapy, low-intensity agents (biologic response modifiers) include: ATG, cyclosporine, and lenalidomide, all of which have shown some efficacy in phase II and phase III trials. Use of IST with ATG, with or without cyclosporine, has been shown in several studies to be most efficacious in MDS patients with HLA-DR15 histocompatibility type, marrow hypoplasia, normal cytogenetics, low-risk disease, and evidence of a PNH clone. Researchers from the NIH have updated their analysis of 129 patients treated with IST with equine ATG alone, cyclosporine alone, or in...
combination. This study demonstrated markedly improved response rates in the subgroup of patients 60 years of age or younger with IPSS int-1 risk or patients with high response probability characteristics as indicated by their prior criteria (ie, age, number of transfusions, possibly HLA-DR15 status).

Although equine ATG has been found more effective than rabbit ATG for treating AA, only limited data within the setting of MDS are available regarding the comparative effectiveness of the two ATG formulations. In a relatively small phase II study in patients with MDS (N = 35; primarily RA subtype), both equine and rabbit ATG were shown to be feasible and active. Some institutions have used tacrolimus in place of cyclosporine A based on the limited data that showed similar efficacy with lower incidence of adverse events in children with AA.

A recent study showed that STAT3 mutant cytotoxic T-lymphocyte clones are present in a small proportion (5%) of MDS patients (including those lacking LGLs), which is associated with HLA-DR15 positivity, marrow hypocellularity, and neutropenia. Despite lack of a survival difference in the STAT3-mutated versus non-mutated MDS patients treated with IST in this small cohort, these findings suggest that STAT3-mutant cytotoxic T-lymphocyte clones may facilitate persistently dysregulated autoimmune activation akin to that present in other MDS patients responsive to IST.

Lenalidomide (a thalidomide analog) is an immunomodulating agent with activity in patients with lower-risk MDS. Beneficial results have been particularly evident for patients with the del(5q) chromosomal abnormality. A multicenter phase II trial of lenalidomide (10 mg/d for 21 days every 4 weeks or 10 mg daily) in anemic RBC-TD MDS patients with del(5q), with or without additional cytogenetic abnormalities (N = 148), demonstrated that the hematologic response to lenalidomide was rapid (median time to response, 4.6 weeks; range, 1–49 weeks) and sustained. RBC-TI (assessed at 24 weeks) occurred in 67% of patients; among patients with IPSS low/int-1 risk (n = 120), 69% achieved T.I. Cytogenetic responses were achieved in 62 of 85 evaluable patients (73%); 45% had a complete cytogenetic response. The most common grade 3 or 4 adverse events included myelosuppression (neutropenia, 55%; thrombocytopenia, 44%), which often required treatment interruption or dose reduction. Thus, careful monitoring of blood counts during the treatment period is mandatory when using this agent, particularly in patients with renal dysfunction (due to the drug’s renal route of excretion). Lenalidomide has been approved by the FDA for the treatment of TD anemia in IPSS low/int-1–risk MDS patients with del(5q) with or without additional cytogenetic abnormalities.

A phase III randomized controlled trial compared the activity of lenalidomide (5 mg/d for 28 days or 10 mg/d for 21 days every 28 days) versus placebo in RBC-TD patients (N = 205) with lower-risk MDS (IPSS low- and int-1 risks) and del(5q). The primary endpoint of RBC-TI greater than or equal to 26 weeks was achieved in a significantly greater proportion of patients treated with lenalidomide (5 mg or 10 mg) versus placebo (37% vs. 57% vs. 2%, respectively; P ≤ .0001 for both lenalidomide groups vs. placebo). Among patients achieving RBC-TI with lenalidomide, onset of erythroid response was rapid, with a median time of 4.2 weeks and 4.3 weeks in the 5-mg and 10-mg lenalidomide groups, respectively. Cytogenetic response rates were significantly higher for the lenalidomide 5-mg (23%; P = .0299) and 10-mg (57%; P < .0001) groups compared with placebo (0%); CR rates were observed in 12% and 35% of patients in the lenalidomide 5-mg and 10-mg arms, respectively. The estimated 2-year cumulative risk to AML progression was 17% (95% CI, 8.7–
33.3), 12.6% (95% CI, 5.4–27.7), and 16.7% (95% CI, 8.3–32.0) in the lenalidomide 5-mg, 10-mg, and placebo groups, respectively. This increased to 35% (95% CI, 21.4–54.6), 31% (95% CI, 18.1–48.8), and 43.3% (95% CI, 27.6–63.1), respectively, at the estimated 4-year mark. The median OS among the lenalidomide 5-mg, 10-mg, and placebo groups (3.5 vs. 4.0 vs. 2.9 years, respectively) was not statistically significantly different; however, median survival was significantly longer in patients who achieved RBC-TI (5.7 years; 95% CI, 3.2–no response) compared to nonresponders (2.7 years; 95% CI, 2.0–4.7). The most common grade 3 or 4 adverse events were myelosuppression and deep vein thrombosis (DVT). Grade 3 or 4 neutropenia was reported in 77%, 75%, and 16% of patients and thrombocytopenia occurred in 37%, 38%, and 2% of patients in the lenalidomide 5-mg, 10-mg, and placebo arms, respectively. Grade 3 or 4 DVT occurred in 3 patients in the lenalidomide 10-mg arm and in one patient in the placebo arm.282

A recent comparative analysis evaluated outcomes of patients with RBC-TD IPSS low/int-1–risk MDS with del(5q) receiving lenalidomide (based on data from the two aforementioned trials [n = 295]) compared with no treatment (based on data from untreated patients in a multicenter registry [n = 125]).283 Untreated patients from the registry had received BSC, including RBC transfusion, iron chelation therapy, and/or ESAs. The 2-year cumulative incidence of AML progression was 7% with lenalidomide and 12% in the untreated cohort; the corresponding 5-year rates were 23% and 20%, respectively; the median time to AML progression had not been reached in either cohort at the time of publication. Lenalidomide was not a significant factor for AML progression in either univariate or multivariate analyses. The 2-year OS probabilities were 90% with lenalidomide and 74% in the untreated cohort; the corresponding 5-year OS probabilities were 54% and 40.5%, respectively, with a median OS of 5.2 years and 3.8 years (P = .755).283 Based on multivariate analysis using Cox proportional hazard models with left truncation, lenalidomide was associated with a significantly decreased risk of death compared with no treatment (HR, 0.597; 95% CI, 0.399–0.894; P = .012). Other independent factors associated with a decreased risk of death were female sex, higher hemoglobin levels, and higher platelet counts. Conversely, independent factors associated with increased risk of death included older age and greater RBC transfusion burden.283

A phase II study evaluated lenalidomide treatment in RBC-TD patients (N = 214) with low- or int-1–risk MDS without del(5q).284 Results showed that 26% of the non-del(5q) patients (56 of 214) achieved TI after a median of 4.8 weeks of treatment. TI continued for a median duration of 41 weeks. The median rise in hemoglobin was 3.2 g/dL (range, 1.0–9.8 g/dL) for those achieving TI. A 50% or greater reduction in transfusion requirement was noted in an additional 37 patients (17%), yielding an overall rate of hematologic improvement of 43%. The most common grade 3 or 4 adverse events were neutropenia (30%) and thrombocytopenia (25%).

An international phase III study of 239 patients with IPSS low- or int-1–risk MDS and RBC-TD and lacking the del(5q) abnormality evaluated the role of lenalidomide treatment.269 Patients receiving lenalidomide (n = 160) compared to placebo (n = 79) had a higher rate of RBC-TI (26.9% vs. 2.5%; P < .001) that lasted a median duration of 31 weeks (95% CI, 20.7–59.1 weeks). TI persisting greater than 8 weeks was seen in 27% of patients receiving lenalidomide versus 2.5% of patients in the placebo cohort (P < .001). Overall, 90% of patients had disease that responded to therapy within 16 weeks. Transfusion reduction of 4 or more units of packed RBCs was seen in 22% of lenalidomide-treated patients while no reduction was seen in the placebo group. Incidence of
treatment-related mortality was 2.5% in both groups; however, the incidence of myelosuppression was higher in the lenalidomide-treated group. In comparing the patients receiving lenalidomide versus placebo, the incidence of grade 3 or 4 neutropenia was 61.9% versus 12.7%, respectively, and the rate of thrombocytopenia was 35.6% versus 3.8%, respectively.269 Further evaluation in more extended clinical trials is needed to determine the efficacy of this drug and other agents for non-del(5q) MDS patients, particularly addressing the characterization of the subgroup of patients with MDS who responded to lenalidomide. The NCCN Guidelines Panel recommends lenalidomide be considered for patients with symptomatically anemic non-del(5q) MDS with anemia that did not respond to initial therapy.

A phase III randomized trial in lower-risk, ESA-refractory, non-del(5q) patients compared lenalidomide alone (10 mg/d for 21 days every 28 days) with patients receiving lenalidomide in conjunction with rHu Epo (60,000 U/wk).285 Erythroid response after 4 treatment cycles was 23.1% (95% CI, 13.5–35.2) versus 39.4% (95% CI, 27.6–52.2; \( P = .044 \)), respectively. Overall RBC-TI was not statistically different between groups (13.8% vs. 24.2%; \( P = .13 \)). However, in a subgroup analysis that excluded heavily RBC-TD patients (defined as receiving greater than 4 RBC units per 8 weeks) a statistically significant improvement was seen with the addition of rHu Epo (47% vs. 16%; \( P = .04 \)), suggesting that lenalidomide may restore sensitivity of MDS erythroid precursors to Epo.285

**High-Intensity Therapy**

High-intensity therapy includes intensive induction chemotherapy or HCT.3,286 Although these approaches have the potential to change the natural history of the disease, there is an attendant greater risk of regimen-related morbidity and mortality. The panel recommends that such treatments be given in the context of clinical trials. Comparative studies have not shown benefit between the different intensive chemotherapy regimens (including idarubicin-, cytarabine-, fludarabine-, and topotecan-based regimens) in MDS.287

A high degree of multi-drug resistance occurs in marrow hematopoietic precursors from patients with advanced MDS and is associated with decreased responses and shorter response durations in patients treated with many of the standard chemotherapy induction regimens. Thus, chemotherapeutic agents used to treat “resistant-type” AML, and agents that modulate this resistance, are now being evaluated for the treatment of patients with advanced MDS. Ongoing clinical trials evaluating multi-drug resistance modulators are important, as both positive289,290 and negative291 studies have been published.

Allogeneic HCT from an HLA-matched sibling or matched unrelated donor is a preferred approach for treating select patients with MDS, particularly those with high-risk disease.292-299 This includes both standard and RIC strategies. AzA, decitabine, or other therapies may be used as a bridge to transplantation. These agents should not be used to delay HCT in patients who have available donors. In patients who relapse after a prolonged remission following the first transplant, a second transplant or donor lymphocyte infusion immune-based therapy may be considered. Allogeneic HCT may also be considered in select lower-risk MDS patients (IPSS int-1, IPSS-R, and WPSS intermediate) with severe cytopenias. Whether transplants should be performed before or after patients achieve remission following induction chemotherapy has not been prospectively established.300 Comparative clinical trials are needed to address these issues.
NCCN Guidelines Version 2.2018
Myelodysplastic Syndromes

Recommended Treatment Approaches

Therapy for Lower-Risk Patients (IPSS Low, Intermediate-1; IPSS-R Very Low, Low, Intermediate; or WPSS Very Low, Low, Intermediate)

Regarding the therapeutic options for lower-risk patients with clinically significant cytopenias or increased bone marrow blasts, the NCCN Guidelines Panel recommends stratifying these patients into several groups. Patients with del(5q) chromosomal abnormalities alone or with one other cytogenetic abnormality, except those involving chromosome 7, and symptomatic anemia should receive lenalidomide. Studies have shown the relative safety of lenalidomide in these patients and improved QOL outcomes in randomized clinical trials. The recommended dose of lenalidomide in this setting is 10 mg/d for 21 days, every 28 days, or 28 days monthly; response should be assessed 2 to 4 months after initiation of treatment. In patients with a clinically significant decrease in neutrophil or platelet counts, caution is required and may warrant either use of a modified dose of lenalidomide or withdrawing lenalidomide as an option. In the previously discussed phase III trial with lenalidomide in patients with del(5q), patients with low neutrophil counts (<500 cells/mcL) or platelet counts (<25,000 cells/mcL) were excluded from the study. An alternative option to lenalidomide in patients with del(5q) and symptomatic anemia may include an initial trial of ESAs in cases where sEpo levels are 500 mU/mL or less. If no response is seen to lenalidomide, these patients should follow treatment options for patients without the del(5q) abnormality.

Patients without the del(5q) abnormality, alone or with one other cytogenetic abnormality and with symptomatic anemia, are categorized on the basis of sEpo levels. Levels of less than or equal to 500 mU/mL should be treated with ESAs (rHu Epo or darbepoetin) with or without G-CSF (see Evaluation of Related Anemia/Treatment of Symptomatic Anemia in the algorithm). Patients with normal cytogenetics, less than 15% ring sideroblasts, and sEpo levels of 500 mU/mL or less may respond to Epo if relatively high doses are administered. The Epo dose required is 40,000 to 60,000 SC units 1 to 2 times a week. Darbepoetin alfa should be given subcutaneously at a dose of 150 to 300 mcg every other week. Erythroid responses generally occur within 6 to 8 weeks of treatment. A more prompt response may be obtained with a higher starting dose. The above recommended Epo dose is much higher than the dose needed to treat renal causes of anemia wherein marrow responsiveness would be relatively normal. However, if a response occurs at the higher dose, the recommendation is to attempt a decrease to the lowest effective dose. The literature supports either daily dosing or dosing 2 to 3 times per week.

Iron repletion needs to be verified before instituting Epo or darbepoetin therapy. If no response occurs with these agents alone, the addition of G-CSF should be considered. Evidence suggests that G-CSF (and, to a lesser extent, GM-CSF) has synergistic erythropoietic activity when used in combination and markedly enhances the erythroid response rates due to enhanced survival of red cell precursors. This is particularly evident for patients with greater than or equal to 15% ring sideroblasts in the marrow (and sEpo level ≤500 mU/mL) as the very low response rates to Epo or darbepoetin alone in this subgroup are markedly enhanced when combined with G-CSF.

For the erythroid synergistic effect, relatively low doses of G-CSF are needed to help normalize the neutrophil count in initially neutropenic patients or to double the neutrophil count in patients who are initially non-neutropenic. For this purpose, an average of 1 to 2 mcg/kg SC G-CSF is administered either daily or 1 to 2 times per week. Detection of erythroid responses generally occurs within 6 to 8 weeks of treatment. If no response occurs within this time frame, treatment...
should be considered a failure and discontinued. In the case of treatment failure, one should rule out and treat deficient iron stores. Clinical trials or supportive care are also treatment options for these patients. A validated decision model has been developed for predicting erythroid responses to Epo plus G-CSF based on the patient’s basal sEpo level and number of previous RBC transfusions. This cytokine treatment is not suggested for patients with endogenous sEpo levels greater than 500 mU/mL due to the very low erythroid response rate to these drugs in this patient population.

In patients who do not respond by 3 months or who have an erythroid response that is followed by a loss of response, lenalidomide may be combined with ESAs, with or without G-CSF. If no response is seen after 4 months, non-responders should be considered for IST (ATG, with or without cyclosporine) if there is a high likelihood of response to such therapy. In patients with lower-risk MDS, the most appropriate candidates for IST include: 1) patients who are age 60 years or younger with less than or equal to 5% marrow blasts; 2) patients who have hypocellular marrows; 3) patients with PNH clone positivity; or 4) patients with STAT-3 mutant cytotoxic T-cell clones.

Alternatively, treatment with AzaC, decitabine, or lenalidomide should be considered for patients predicted to have a poor probability of responding or who have not responded to IST. A phase II prospective study of MDS patients who were IPSS low or int-1 with symptomatic anemia with disease that was not expected to respond or that failed to respond to Epo, showed that AzaC was well-tolerated. Although neutropenia and thrombocytopenia were adverse events (47% and 19% of patients, respectively), these toxicities were transient. Other non-hematologic toxicities were mild. AzaC treatment was effective in 60% of patients in the study. Patients with no response to hypomethylating agents or lenalidomide in this setting should be considered for participation in a clinical trial with other relevant agents, or for allogeneic HCT (see Therapy for Higher-Risk Patients).

Anemic patients with sEpo levels greater than 500 mU/mL should be evaluated to determine whether they would be good candidates for IST. Non-responders to IST would be considered for treatment with AzaC, decitabine, or a clinical trial. Patients with sEpo levels greater than 500 mU/mL who have a low probability of responding to IST should be considered for treatment with AzaC, decitabine, or lenalidomide. Non-responders to these treatments could be considered for a clinical trial or for allogeneic HCT.

Patients without symptomatic anemia, who have other clinically relevant cytopenias (particularly clinically severe thrombocytopenia) or increased bone marrow blasts should be considered for treatment with AzaC, decitabine, IST (if there is a good probability of responding to these agents), or a clinical trial. If there is disease progression or no response, allogeneic HCT can be considered in select lower-risk MDS patients (IPSS int-1, IPSS-R, and WPSS intermediate patients) with severe cytopenias. TPO agonists may also be considered in these patients.

While these guidelines provide a framework in which to treat MDS patients, careful monitoring for disease progression and consideration of the patient’s preferences remain major factors in the decision and timing of the treatment regimen initiated.

**Therapy for Higher-Risk Patients (IPSS Intermediate-2, High; IPSS-R Intermediate, High, Very High; or WPSS High, Very High)**

Treatment for higher-risk patients is dependent on whether they are possible candidates for intensive therapy (eg, allogeneic HCT, intensive chemotherapy). Clinical features relevant for this determination include...
patient age, performance status, absence of major comorbid conditions, psychosocial status, patient preference, and availability of a suitable donor and caregiver. Patients may be taken immediately to transplant or bridging therapy can be used to decrease marrow blasts to an acceptable level prior to transplant. The patient’s personal preference for type of therapy needs particular consideration. Regardless, supportive care should be provided for all patients.

**Intensive Therapy**

**Allogeneic Hematopoietic Cell Transplantation**

For patients who are transplant candidates, an HLA-matched sibling or HLA-matched unrelated donor can be considered. Results with HLA-matched unrelated donors have improved to levels comparable to those obtained with HLA-matched siblings. With the increasing use of cord blood or HLA-haploidentical related donors, HCT has become a viable option for many patients. High-dose conditioning is typically used for younger patients, whereas RIC for HCT is generally the strategy in older individuals.\(^\text{311}\)

To aid therapeutic decision-making regarding the timing and selection of MDS patients for HCT, a study compared outcomes with HLA-matched sibling HCT in MDS patients 60 years of age or younger to data in non-treated MDS patients from the IMRAW/IPSS database.\(^\text{312}\) Using a Markov decision analysis, this investigation indicated that IPSS int-2 and high-risk patients 60 years of age or younger had the longest life expectancy if transplanted (from HLA-identical siblings) soon after diagnosis, whereas patients with IPSS low risk had the best outlook if HCT was delayed until MDS progressed. For patients in the int-1–risk group, there was only a slight gain in life expectancy if HCT was delayed; therefore, decisions should be made on an individual basis (eg, dependent on platelet or neutrophil counts).\(^\text{312}\) A retrospective study evaluated the impact of the WHO classification and WPSS on the outcome of patients who underwent allogeneic HCT.\(^\text{146}\) The data suggest that lower-risk patients (based on WPSS risk score) do very well following allogeneic HCT, with a 5-year OS of 80%. With increasing WPSS scores, the probability of 5-year survival after HCT declined progressively to 65% (intermediate risk), 40% (high risk), and 15% (very high risk).\(^\text{146}\)

Based on data regarding RIC for transplantation from two studies\(^\text{313,314}\) and two comprehensive reviews of the field,\(^\text{315,316}\) patient age and disease status generally dictated the type of conditioning. Patients older than 55 or 65 years, particularly if they had less than 10% marrow myeloblasts, generally received RIC; if the blast count was high, pre-HCT debulking therapy was often given. Younger patients, regardless of marrow blast burden, most frequently received high-dose conditioning. Variations on these approaches would be considered by the individual transplant physician based on patient features and the specific regimen utilized at that center. Some general recommendations have been presented in a review article.\(^\text{317}\)

There are limited data regarding the use of allogeneic HCT in older adults with MDS; however, studies suggest that age alone should not be an exclusionary factor for eligibility. In a prospective allogeneic transplant trial using nonmyeloablative conditioning, 372 patients between the ages of 60 and 75 years with hematologic malignancies (AML, MDS, chronic lymphocytic leukemia, lymphoma, and multiple myeloma) were shown to have no association between age and non-relapse mortality, OS, and PFS.\(^\text{318}\) The study supports the use of comorbidities and disease status, rather than age alone, as criteria for determining the eligibility of patients for allogeneic HCT.
Other retrospective studies have also evaluated transplant-related mortality in older patients with MDS receiving RIC for allogeneic transplant.\textsuperscript{319,320} No increase in mortality was seen in either study. In a retrospective analysis of 514 patients with de novo MDS (ages 60–70 years), RIC allogeneic transplants were not associated with improved life expectancy for patients with low or int-1 IPSS MDS compared to other non-transplant therapies. However, a potential improvement in life expectancy was seen in patients with int–2– or high-risk IPSS MDS.\textsuperscript{321} It is recognized that there are even fewer data available in regard to patients who are 75 years of age or older.

**Intensive Chemotherapy**
For patients eligible for intensive therapy but lacking a donor hematopoietic cell source, or for patients in whom the marrow blast count requires reduction, consideration should be given to the use of intensive induction chemotherapy.\textsuperscript{322} Although the response rate and durability are lower than for standard AML, this treatment (particularly in clinical trials with novel agents) could be beneficial in some patients. For patients with a potential hematopoietic cell donor who require reduction of tumor burden (ie, to decrease the marrow blast count), achievement of even a partial remission may be sufficient to permit the HCT.

**Non-Intensive Therapy**
For higher-risk patients who do not have a suitable transplant donor and who are not candidates for intensive therapy, the use of AzaC, decitabine, or a relevant clinical trial should be considered. Data from a phase III randomized trial of AzaC showed significantly higher rates of major platelet improvement with AzaC compared with conventional care (33% vs. 14%; \( P = .0003 \)); however, the rates for major neutrophil improvements were similar between AzaC and the control arm (19% vs. 18%).\textsuperscript{251} AzaC or decitabine should be continued for at least 6 cycles of AzaC or 4 cycles of decitabine to assess response to these agents. For patients who show clinical benefit, treatment with hypomethylating agents should be continued as maintenance therapy. Results from a phase III trial comparing decitabine to BSC in higher-risk patients who were ineligible for intensive chemotherapy demonstrated a statistically significant improvement in PFS and reduced AML transformation; improvements in OS and AML-free survivals were also seen, though they did not reach statistical significance.\textsuperscript{253}

Two reports from the phase III, international, multicenter, randomized AZA-001 trial have evaluated AzaC compared to conventional care regimens (CCR) in patients with higher-risk MDS. Patients randomized to the CCR group received the most appropriate of the three protocol-specified CCR options, including AzaC, intensive chemotherapy, or BSC.\textsuperscript{323,324} The OS was increased with AzaC treatment compared to CCR (HR, 0.58; 95% CI, 0.43–0.77; \( P < .001 \)), and a greater number of patients achieved hematologic improvement (49% vs. 29%; \( P < .0001 \)).\textsuperscript{323} The earlier report from the same trial showed improved OS and tolerability in elderly patients (defined as \( \geq 75 \) years of age) with good performance status.\textsuperscript{324} It should be noted that, to date, no head-to-head trials have compared AzaC with decitabine. Therefore, the panel preferentially recommends AzaC (category 1) versus decitabine based on data from the phase III trial that showed superior median survival with AzaC compared to BSC.

**Supportive Care Only**
For patients with adverse clinical features or disease progression despite therapy and the absence of reasonable specific anti-tumor therapy, adequate supportive care should be maintained.

**Summary**
The NCCN Guidelines are based on extensive evaluation of the reviewed risk-based data and indicate current approaches for managing
patients with MDS. Five drugs approved by the FDA for treating specific subtypes of MDS include lenalidomide for patients with del(5q) cytogenetic abnormalities; AzaC and decitabine for treating higher-risk or non-responsive patients; and deferasirox and deferoxamine for iron chelation in the treatment of iron overload. However, as a substantial proportion of MDS patient subsets lack effective treatment for their cytopenias or for altering disease natural history, clinical trials with these and other novel therapeutic agents, along with supportive care, remain the hallmark of disease management. Evaluating the role of thrombopoietic cytokines for the management of thrombocytopenia in MDS and determining the effects of therapeutic interventions on QOL are important issues needing investigation. Progress toward improving the management of MDS has occurred over the past few years and more advances are anticipated with these guidelines providing a framework for coordination of comparative clinical trials.
References


33. Meggendorfer M, Bacher U, Alpermann T, et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia 2013;27:1852-1860. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23628959.


59. Okcu F, Roberts WM, Chan KW. Bone marrow transplantation in Shwachman-Diamond syndrome: report of two cases and review of


131. Quentin S, Cuccioni W, Ceccaldi R, et al. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of


145. Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias...


170. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic...


